var title_f2_55_2928="Pinning of displaced radial head fracture";
var content_f2_55_2928=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F68824&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F68824&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Pinning of displaced radial head fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 244px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Lateral view of elbow with displaced radial head fracture.",
"    <br>",
"     (B) Anatomic reduction with pinning.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Courtesy of Paula Schweich, MD.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_55_2928=[""].join("\n");
var outline_f2_55_2928=null;
var title_f2_55_2929="Accessory AV pathways III";
var content_f2_55_2929=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F62454&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F62454&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Conduction through an accessory pathway with AV nodal delay",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 427px; height: 293px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Compared to conduction through an AP with normal AV node conduction, delayed conduction through the AV node allows more of the ventricular myocardium to be activated by preexcitation (shown in blue). The inset on the right shows the ECG timing of these events. The atrial to His interval is increased due to the AV nodal delay (RA to H); His activation is so delayed that is follows activation caused by the AP (V",
"    <sub>",
"     P",
"    </sub>",
"    ). The PR interval is short due to the preexcitation, the delta wave (arrow) is more pronounced due to the greater and unopposed early forces (blue), and the QRS duration is prolonged due to the later than normal ventricular activation caused by the AV nodal delay (yellow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_55_2929=[""].join("\n");
var outline_f2_55_2929=null;
var title_f2_55_2930="Schema manage suspected AMI ER";
var content_f2_55_2930=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F56813&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F56813&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 619px\">",
"   <div class=\"ttl\">",
"    Algorithm for management of patients with suspected acute myocardial infarction in the emergency department",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 599px; height: 605px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Initial laboratory work should include: serum cardiac biomarkers (cTnI or cTnT preferred), CBC with platelet count, PT and INR, aPTT, electrolytes, magnesium, BUN, creatinine, blood glucose, and serum lipid profile.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_55_2930=[""].join("\n");
var outline_f2_55_2930=null;
var title_f2_55_2931="Nail bed splint";
var content_f2_55_2931=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F72699&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F72699&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nail bed repair: Splinting of the nail bed",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The repaired nail bed is protected by placing the original nail back into the proximal fold (eponychium) and securing it with nonabsorbable suture or wound adhesive (eg, Dermabond&reg;). The nail should undergo trephination prior to replacement to permit drainage. If the nail cannot be used, trimmed sterile foil from the suture pack, a single thickness of nonadherent gauze, or a 0.2 inch silicon sheeting may be placed instead.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Richard A Saladino, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_55_2931=[""].join("\n");
var outline_f2_55_2931=null;
var title_f2_55_2932="Tracheal infections associated with tracheostomy tubes and endotracheal intubation in children";
var content_f2_55_2932=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Tracheal infections associated with tracheostomy tubes and endotracheal intubation in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/55/2932/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/55/2932/contributors\">",
"     Charles R Woods, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/55/2932/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/55/2932/contributors\">",
"     Glenn C Isaacson, MD, FAAP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/55/2932/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/55/2932/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/55/2932/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/55/2932/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tracheal infections associated with tracheostomy tubes and endotracheal intubation in children will be discussed here. The clinical features, diagnosis, treatment, and prevention of bacterial tracheitis in children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/49/32536?source=see_link\">",
"     \"Bacterial tracheitis in children: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28534?source=see_link\">",
"     \"Bacterial tracheitis in children: Treatment and prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Bacterial tracheitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacterial tracheitis is an invasive exudative bacterial infection of the soft tissues of the trachea [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2932/abstract/1\">",
"     1",
"    </a>",
"    ]. It is the focus of this topic review. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/49/32536?source=see_link\">",
"     \"Bacterial tracheitis in children: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Ventilator-associated tracheobronchitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventilator-associated tracheobronchitis (VAT, also called nosocomial tracheobronchitis) has been proposed as a clinical entity distinct from, and possibly a precursor to, ventilator-associated pneumonia (VAP) in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2932/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The existence of VAT as a distinct entity, its intermediary role in development of VAP, and whether early treatment for potential VAT reduces risk for subsequent VAP remain uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2932/abstract/4\">",
"     4",
"    </a>",
"    ]. VAT is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/11/15545?source=see_link&amp;anchor=H20#H20\">",
"     \"Endotracheal tube management and complications\", section on 'Tracheobronchitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children who require artificial airways are at increased risk for bacterial tracheopulmonary infections, including bacterial tracheitis, because of bacterial colonization of the artificial airway and mucosal injuries related to airway cannulation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2932/abstract/5\">",
"     5",
"    </a>",
"    ]. Children with laryngeal diversion and tracheostoma without a tracheostomy tube also may develop bacterial tracheitis, but it is unclear if they have increased risk relative to children with intact airways.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Artificial airways generally are colonized with potentially pathogenic microbes [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2932/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Colonizing bacteria may arise from the upper airway, ventilator tubing or reservoirs, or humidification circuits [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2932/abstract/5\">",
"     5",
"    </a>",
"    ]. Common colonizing bacteria include Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Acinetobacter species, Klebsiella pneumonia, Escherichia coli, Serratia marcescens, Enterobacter species, other gram-negative enteric organisms, and Pseudomonas aeruginosa [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2932/abstract/6-8\">",
"     6-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Airway cannulation can lead to varying degrees of ulceration and mucosal denudation, although healing and regeneration appear to occur over several days [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2932/abstract/9\">",
"     9",
"    </a>",
"    ]. Despite the potential predisposition that such injuries might provide, true artificial airway-related bacterial tracheitis without more prominent lower tract involvement is uncommon.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacterial tracheitis in children with artificial airways may be difficult to distinguish from associated lung infection. Most cases of lower respiratory tract infection in children with artificial airways are accompanied by increased secretions emanating from the tube with or without associated crackles on chest auscultation or pulmonary infiltrates on chest radiographs. Bacterial infections isolated to the trachea may present in a similar fashion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of bacterial tracheitis in children with artificial airways includes [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2932/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Other bacterial infections of the upper or lower respiratory tract infection (eg, sinusitis, pneumonia)",
"     </li>",
"     <li>",
"      Bacterial colonization in the setting of viral respiratory tract infection",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is difficult but important to differentiate bacterial tracheitis from the above conditions, because the treatments may differ. Changes in clinical status, radiographs, and tracheal aspirates together are more helpful than isolated findings [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2932/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of bacterial tracheitis in children with tracheostomy tubes is based upon clinical, radiographic, microbiologic, and tracheoscopic findings as described below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Clinical information",
"    </span>",
"    &nbsp;&mdash;&nbsp;Important aspects of the history include [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2932/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Have monitored oxygen saturations declined?",
"     </li>",
"     <li>",
"      Have secretions changed in color, viscosity, or odor?",
"     </li>",
"     <li>",
"      Has the need for airway suctioning increased (suggesting increased production of exudate)?",
"     </li>",
"     <li>",
"      Has the need for oxygen supplementation or ventilatory support increased?",
"     </li>",
"     <li>",
"      Are there new infiltrates or opacities on chest radiographs?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Artificial-airway-associated bacterial tracheitis is more likely if there have been decreased oxygen saturations, increased volume and purulence of tracheal secretions, increased need for respiratory support, and absence of new pulmonary infiltrates [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2932/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Microbiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tracheal aspirate for Gram stain and culture should be obtained in children with artificial airways in whom bacterial tracheitis is suspected. The current Gram stain (pending culture results) should be compared with previous tracheal aspirate Gram stains and cultures. An increase in semiquantitative number (eg, few to many, 2+ to 4+) of white blood cells (generally neutrophils) and presence of microbes with different morphology (eg, currently gram-positive cocci versus past gram-negative rods, and vice versa) raises suspicion for new bacterial infection over simple colonization [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2932/abstract/5\">",
"     5",
"    </a>",
"    ]. However, it does not help in differentiating tracheal or pulmonary infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Tracheoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tracheoscopy can confirm or exclude the diagnosis of bacterial tracheitis in children with artificial airways [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2932/abstract/5\">",
"     5",
"    </a>",
"    ]. Bacterial tracheitis is confirmed if there is evidence of tracheal inflammation in the setting of increased secretions and Gram stain results suggesting bacterial infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of initial antibiotic therapy in children with artificial-airway-associated bacterial tracheitis is influenced by several factors [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2932/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Susceptibilities of pathogens identified on recent tracheal aspirate cultures (if available)",
"     </li>",
"     <li>",
"      Morphology of organisms of current Gram stain",
"     </li>",
"     <li>",
"      Potential for acquisition of multidrug-resistant flora during recent hospitalizations or stay in long-term care facility",
"     </li>",
"     <li>",
"      The degree of illness of the child",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The antibiotic regimen can be tailored as indicated when the results of the current tracheal aspirate and culture and susceptibility tests are available.",
"   </p>",
"   <p>",
"    The duration of antimicrobial therapy for artificial-airway-associated bacterial tracheitis has not been systematically studied. Seven to 10 days generally should be sufficient. As an alternative, antimicrobial therapy may be continued until a few days after resolution of respiratory tract symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children who require artificial airways are at increased risk for bacterial tracheopulmonary infections because of bacterial colonization of the artificial airway and mucosal injuries related to airway cannulation. True artificial-airway-related bacterial tracheitis without more prominent lower tract involvement is uncommon. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Overview'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical features of tracheopulmonary infection in children with tracheostomy or endotracheal tubes include increased secretions emanating from the tube, crackles on chest auscultation, or pulmonary infiltrates on chest radiographs. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of bacterial tracheitis in children with artificial airways is based upon clinical, radiographic, microbiologic, and tracheoscopic findings (see",
"      <a class=\"local\" href=\"#H9\">",
"       'Diagnosis'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Clinical &mdash; Increased tracheal secretions, increased need for respiratory support",
"     </li>",
"     <li>",
"      Radiographic &mdash; Absence of new pulmonary infiltrate",
"     </li>",
"     <li>",
"      Microbiologic &mdash; Increased white blood cells",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      organisms with different morphology compared with previous Gram stains",
"     </li>",
"     <li>",
"      Tracheoscopic &mdash; Tracheal inflammation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bacterial tracheitis in children with artificial airways is treated with antimicrobial therapy. Initial antimicrobial therapy is individualized according to susceptibilities of recent tracheal aspirate pathogens (if available), current Gram stain results, potential for multidrug-resistant pathogens, and the degree of illness. The regimen is tailored as indicated when the results of the tracheal aspirate culture and susceptibility tests are available. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2932/abstract/1\">",
"      Jones R, Santos JI, Overall JC Jr. Bacterial tracheitis. JAMA 1979; 242:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2932/abstract/2\">",
"      Nseir S, Ader F, Marquette CH. Nosocomial tracheobronchitis. Curr Opin Infect Dis 2009; 22:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2932/abstract/3\">",
"      Craven DE. Ventilator-associated tracheobronchitis (VAT): questions, answers, and a new paradigm? Crit Care 2008; 12:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2932/abstract/4\">",
"      Dallas J, Kollef M. VAT vs VAP: are we heading toward clarity or confusion? Chest 2009; 135:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2932/abstract/5\">",
"      Graf J, Stein F. Tracheitis in pediatric patients. Semin Pediatr Infect Dis 2006; 17:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2932/abstract/6\">",
"      Brook I. Bacterial colonization, tracheobronchitis, and pneumonia following tracheostomy and long-term intubation in pediatric patients. Chest 1979; 76:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2932/abstract/7\">",
"      Morar P, Singh V, Makura Z, et al. Oropharyngeal carriage and lower airway colonisation/infection in 45 tracheotomised children. Thorax 2002; 57:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2932/abstract/8\">",
"      Niederman MS, Ferranti RD, Zeigler A, et al. Respiratory infection complicating long-term tracheostomy. The implication of persistent gram-negative tracheobronchial colonization. Chest 1984; 85:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2932/abstract/9\">",
"      Friedberg SA, Griffith TE, Hass GM. Histologic changes in the trachea following tracheostomy. Ann Otol Rhinol Laryngol 1965; 74:785.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6045 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.243-684EC2BD62-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_55_2932=[""].join("\n");
var outline_f2_55_2932=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Bacterial tracheitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Ventilator-associated tracheobronchitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Clinical information",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Microbiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Tracheoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/49/32536?source=related_link\">",
"      Bacterial tracheitis in children: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28534?source=related_link\">",
"      Bacterial tracheitis in children: Treatment and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/11/15545?source=related_link\">",
"      Endotracheal tube management and complications",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_55_2933="Lipoma arborescens MRI";
var content_f2_55_2933=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F57209&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F57209&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 637px\">",
"   <div class=\"ttl\">",
"    Magnetic resonance imaging of lipoma arborescens explaining dry tap",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 617px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Failed arthrocentesis due to chronic synovitis with lipoma arborescens in a patient with psoriatic arthritis. T1 weighted (left) and T2 weighted (right) axial images through the mid-pole of the patella show massive frond-like, fatty proliferation of the synovium both on the medial and lateral sides of the joint (short arrows). Although a large joint effusion is present (E), placement of a needle, particularly from the medial side (long arrow) would probably enter the hypertrophied synovium and would fail to yield fluid. Aspiration of 10 mL of low-viscosity, inflammatory fluid was achieved by the lateral approach.",
"    <div class=\"footnotes\">",
"     M: medial; L: lateral.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Roberts WN, Hayes CW, Breitbach SA, et al. Am J Med 1996; 100:461.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_55_2933=[""].join("\n");
var outline_f2_55_2933=null;
var title_f2_55_2934="Achalasia";
var content_f2_55_2934=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"topicTitle\">",
"   Patient information: Achalasia (Beyond the Basics)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/55/2934/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/55/2934/contributors\">",
"     Stuart J Spechler, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/55/2934/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/55/2934/contributors\">",
"     J Thomas LaMont, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/55/2934/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/55/2934/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/55/2934/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     ACHALASIA OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Achalasia is an uncommon swallowing disorder that affects about 1 in every 100,000 people. The major symptom of achalasia is usually difficulty with swallowing. Most people are diagnosed between the ages of 25 and 60 years. Although the condition cannot be cured, the symptoms can usually be controlled with treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ACHALASIA CAUSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In achalasia, nerve cells in the esophagus (the tube that carries food from the mouth to the stomach) degenerate for reasons that are not known. The loss of nerve cells in the esophagus causes two major problems that interfere with swallowing (",
"    <a class=\"graphic graphic_figure graphicRef79301 \" href=\"UTD.htm?8/28/8642\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The muscles that line the esophagus do not contract normally, so that swallowed food is not propelled through the esophagus and into the stomach properly.",
"     </li>",
"     <li>",
"      The lower esophageal sphincter (LES), a band of muscle that encircles the lower portion of the esophagus, does not function correctly.",
"      <br/>",
"      <br/>",
"      Normally, the LES relaxes when we swallow to allow swallowed food to enter the stomach. When the food has moved through the esophagus into the stomach, the LES muscle contracts to squeeze the end of the esophagus closed, thus preventing the stomach contents from flowing backwards (refluxing) into the esophagus.",
"      <br/>",
"      <br/>",
"      In people with achalasia, the LES fails to relax normally with swallowing. Instead, the LES muscle continues to squeeze the end of the esophagus, creating a barrier that prevents food and liquids from passing into the stomach (",
"      <a class=\"graphic graphic_figure graphicRef69107 \" href=\"UTD.htm?0/40/643\">",
"       figure 2",
"      </a>",
"      ). Over time, the esophagus above the persistently contracted LES dilates, and large volumes of food and saliva can accumulate in the dilated esophagus.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ACHALASIA SYMPTOMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common symptom of achalasia is difficulty swallowing. Patients often experience the sensation that swallowed material, both solids and liquids, gets stuck in the chest. This problem often begins slowly and progresses gradually. Many people do not seek help until symptoms are advanced. Some people compensate by eating more slowly and by using maneuvers, such as lifting the neck or throwing the shoulders back, to improve emptying of the esophagus.",
"   </p>",
"   <p>",
"    Other symptoms can include chest pain, regurgitation of swallowed food and liquid, heartburn, difficulty burping, a sensation of fullness or a lump in the throat, hiccups, and weight loss.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ACHALASIA DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Achalasia may be suspected based upon symptoms, but tests are needed to confirm the diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Chest x-rays",
"    </span>",
"    &nbsp;&mdash;&nbsp;A chest x-ray may reveal a dilated esophagus and absence of air in the stomach. However, a chest x-ray is not adequate for a diagnosis of achalasia and further testing is required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Barium swallow test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?18/37/19028?source=see_link\">",
"     barium",
"    </a>",
"    swallow test is a common screening test for achalasia. The test involves swallowing a chalky-tasting, thick mixture of barium while x-rays are taken. The barium shows the outline of the esophagus and lower esophageal sphincter (LES) (",
"    <a class=\"graphic graphic_figure graphicRef69107 \" href=\"UTD.htm?0/40/643\">",
"     figure 2",
"    </a>",
"    ). Characteristic findings of achalasia on barium swallow include a persistently narrowed region at the end of the esophagus (the LES), with a dilated esophagus above the narrowed region. The barium swallow may also show spastic contractions in the esophagus above the LES, a condition called &ldquo;vigorous achalasia&rdquo;.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Manometry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Manometry is a test that measures changes in pressures within the esophagus that are caused by the contraction of the muscles that line the esophagus. The test involves the passage of a thin tube through the mouth or nose into the esophagus. The tube is lined by numerous pressure sensors that convey pressures within the esophagus to a device that records those pressures. Patients are usually instructed to have nothing to eat or drink for eight hours before the test, and they are given sips of water to swallow while the tube is in place.",
"   </p>",
"   <p>",
"    Manometry is almost always used to confirm the diagnosis of achalasia. The test typically reveals three abnormalities in people with achalasia: high pressure in the LES at rest, failure of the LES to relax after swallowing, and an absence of useful (peristaltic) contractions in the lower esophagus. The last two features are the most important and are required to make the diagnosis of achalasia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Endoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopy allows the physician to see the inside of the esophagus, LES, and stomach using a thin, lighted, flexible tube. Most patients are given sedatives during the endoscopy procedure. This test is usually recommended for people with suspected achalasia and is especially useful for detecting other conditions that can mimic achalasia such as cancer of the upper portion of the stomach. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?21/0/21506?source=see_link\">",
"     \"Patient information: Upper endoscopy (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In people with achalasia, endoscopy often reveals a dilated esophagus that contains retained food; it may also reveal inflammation, small ulcers caused by residual food or pills, and candida (yeast) infection.",
"   </p>",
"   <p>",
"    The endoscope can be advanced through the LES and into the stomach to check for stomach cancer. Cancer in the upper part of the stomach can produce symptoms and abnormal manometry results that are virtually identical to those of achalasia. This condition is called pseudoachalasia (meaning \"false\" achalasia) or secondary achalasia. Biopsies (small samples of tissue) are often obtained in the lower portion of the esophagus to look for cancer cells. Having a biopsy of the esophagus taken during endoscopy is not painful and is generally a safe procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ACHALASIA TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several options are available for the treatment of achalasia. Unfortunately, none can stop or reverse the underlying loss of nerve cells in the esophagus of patients with achalasia. However, the treatments are usually effective for improving symptoms.",
"   </p>",
"   <p>",
"    None of the available treatments are expected to restore normal (peristaltic) contractions in the esophagus of patients with achalasia. Rather, the treatments aim to weaken the lower esophageal sphincter (LES) muscle to the point that it no longer poses a barrier to the passage of food. The LES can be weakened by drugs, or mechanically by procedures that tear or cut the LES muscle.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Drug therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two classes of drugs, nitrates and calcium channel blockers, have LES muscle-relaxing effects. These drugs can decrease symptoms in people with achalasia. The drugs are usually taken by placing a pill under the tongue 10 to 30 minutes before meals.",
"   </p>",
"   <p>",
"    Drug therapy is the least invasive and safest option for treating achalasia. However, most people find that long-term drug therapy is inconvenient, ineffective, and often associated with unpleasant side effects, such as headache and low blood pressure. Furthermore, the drugs tend to become less effective over time. For these reasons, medications are recommended primarily for patients who are not interested in or not healthy enough for mechanical treatments such as balloon dilation and surgery (myotomy).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Balloon dilation (pneumatic dilatation)",
"    </span>",
"    &nbsp;&mdash;&nbsp;For balloon dilation, the patient swallows a collapsed balloon that is positioned in the LES. An x-ray machine is often used to guide placement of the balloon. When the balloon has been positioned at the LES, it is inflated abruptly to a large size in order to tear the muscle of the LES. This procedure is effective for relieving the swallowing difficulty in patients with achalasia in approximately two-thirds of people, although chest pain persists in some. Patients frequently require more than one balloon dilation treatment for adequate relief.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;If you have balloon dilation, you will be asked to drink only liquids for 12 hours to two days in advance (a longer period is recommended if you have a great deal of food retention in the esophagus). Using endoscopy and fluoroscopy (x-ray), a physician advances a guide wire down the esophagus and positions it inside the LES. A deflated balloon is then advanced along this guide wire, positioned inside the LES, and inflated for a variable period ranging from seconds to minutes. The balloon is then deflated and withdrawn, and you are monitored in a recovery area for a number of hours to detect any complications. After the balloon dilation, some physicians routinely perform an x-ray test similar to the",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?18/37/19028?source=see_link\">",
"     barium",
"    </a>",
"    swallow described above to make sure that the balloon has not created a hole (perforation) in the esophagus. If there are no complications, you can usually resume eating when you have recovered from the procedure. If your day-to-day symptoms do not improve, additional dilations can be performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Success rate",
"    </span>",
"    &nbsp;&mdash;&nbsp;A single balloon dilation session continues to relieve symptoms of achalasia in about 60 percent of people one year after the procedure and in about 25 percent of people five years after the procedure. Higher success rates have been reported in some studies. The success rate after longer periods has not been well studied, but some people have remained symptom-free for as long as 25 years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;About 15 percent of people experience severe chest pain immediately after balloon dilation and some experience fever.",
"   </p>",
"   <p>",
"    The most serious complication of balloon dilation is creation of a hole (perforation) in the wall of the esophagus; this complication occurs in about 2 to 6 percent of people undergoing the procedure. Symptoms of persistent or worsening pain in the hours after the procedure may indicate a perforation.",
"   </p>",
"   <p>",
"    Perforations of the esophagus after balloon dilation are usually small. For the treatment of small perforations, your doctor will probably admit you to the hospital for intravenous feeding and antibiotic treatment. This usually results in healing of the perforation within one week without surgery. Large perforations will require emergency surgery for repair. In some cases, your doctor might recommend surgery even for a small perforation. A key factor in the successful treatment of perforation of the esophagus is rapid identification of the perforation and rapid implementation of treatment. You should call your physician immediately if you experience increasing pain after balloon dilation, especially if you develop a fever or chills.",
"   </p>",
"   <p>",
"    Bleeding is another important, but infrequent complication of balloon dilation. This complication usually occurs immediately after the dilation. Symptoms of bleeding include dizziness or fainting, especially on standing up, vomiting of blood or material that looks like coffee grounds, and the passage of black or bloody stools. You should notify your doctor immediately if you experience these symptoms.",
"   </p>",
"   <p>",
"    Patients also can develop gastroesophageal reflux disease (GERD) after balloon dilation. Because the LES is the principal barrier that prevents stomach contents from refluxing (backwashing) into the esophagus, LES disruption by balloon dilation can lead to acid reflux. GERD occurs in about 2 percent of people after balloon dilation, but is usually easily controlled with acid-reducing medications. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?37/30/38373?source=see_link\">",
"     \"Patient information: Acid reflux (gastroesophageal reflux disease) in adults (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Surgery (myotomy)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myotomy is an operation that is used to weaken the LES by cutting its muscle fibers. The most common surgical technique used to treat achalasia is called the Heller myotomy, in which the surgeon cuts the muscles at the end of the esophagus and at the top of the stomach. In the past, this surgery was performed through a large (open) incision in the chest or abdomen. Today, this surgery is usually performed laparoscopically, using instruments and a television camera that are passed into the abdomen through small abdominal incisions. People who undergo laparoscopic myotomy are given general anesthesia, and generally stay in the hospital for one to two days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Success rate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery relieves symptoms in 70 to 90 percent of people. Symptom relief is sustained in about 85 percent of people 10 years after surgery and in about 65 percent of people 20 years after the surgery. Thus, some consider surgery to be a more definitive treatment for achalasia than balloon dilation or botulinum toxin injection (see below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postoperative pain is expected, and is treated with pain medications. Like balloon dilation, there is a risk of acid reflux following myotomy, which can cause damage to the esophagus over time.",
"   </p>",
"   <p>",
"    During the operation for myotomy, surgeons often perform an additional procedure called a fundoplication in which a portion of the stomach is wrapped around the esophagus to prevent the reflux of stomach contents (",
"    <a class=\"graphic graphic_figure graphicRef72609 \" href=\"UTD.htm?39/45/40671\">",
"     figure 3",
"    </a>",
"    ). However, the fundoplication does not always prevent reflux, and it can cause additional complications such as difficulty swallowing, bloating, flatulence, and diarrhea. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?37/30/38373?source=see_link\">",
"     \"Patient information: Acid reflux (gastroesophageal reflux disease) in adults (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Botulinum toxin injection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Botulinum toxin injections temporarily paralyze the nerves that signal the LES to contract, thereby helping to relieve the obstruction. Botulinum toxin injection also is used occasionally as a diagnostic test for people who appear to have achalasia but who have inconclusive test results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The injection procedure is performed during endoscopy, while the patient is sedated. The botulinum toxin is injected through the lining of the esophagus directly into the LES muscle.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Success rate",
"    </span>",
"    &nbsp;&mdash;&nbsp;A single botulinum toxin injection session relieves symptoms in 65 to 90 percent of people in the short term (three months to approximately one year). Additional injections can relieve symptoms in patients whose symptoms return. Botulinum toxin injection is more likely to be effective in people over the age of 50 years and in people who have the vigorous form of achalasia.",
"   </p>",
"   <p>",
"    When compared with balloon dilation, botulinum toxin has a similar effectiveness for relieving symptoms in the first one to two years after the procedure; however, prolonged effectiveness requires multiple botulinum toxin injections because the paralyzing effect of the toxin is temporary. The long-term safety and effectiveness of botulinum toxin injection are unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;About 25 percent of people have chest pain for a few hours after the procedure and about 5 percent develop heartburn. Damage to the esophageal wall and lining are rare. The short-term safety of botulinum toxin injection is greater than the short-term safety of both balloon dilation and surgery; this greater short-term safety may make botulinum toxin injection a better choice for patients with other serious medical conditions (eg, advanced age, severe heart or lung problems) who cannot tolerate a balloon dilation or myotomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     LONG-TERM RISK OF ESOPHAGEAL CANCER",
"    </span>",
"    &nbsp;&mdash;&nbsp;People with achalasia have an increased risk of developing esophageal cancer. Your doctor might recommend endoscopy for early detection of this cancer. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?21/0/21506?source=see_link\">",
"     \"Patient information: Upper endoscopy (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     ACHALASIA FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since none of the treatments for achalasia cure the underlying disease, regular follow-up is needed. The goal is to recognize and treat recurrent symptoms or complications of treatment (eg, acid reflux) early. Recognizing and treating these problems can help to prevent the development of severe enlargement of the esophagus (mega-esophagus) and cancer, which could require surgical removal of the entire esophagus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     WHERE TO GET MORE INFORMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"   </p>",
"   <p>",
"    This article will be updated as needed on our web site (",
"    <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"     www.uptodate.com/patients",
"    </a>",
"    ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1804546013\">",
"    <span class=\"h2\">",
"     Patient level information",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11443878\">",
"    <span class=\"h3\">",
"     The Basics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"   </p>",
"   <p>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?19/50/20258?source=see_link\">",
"     Patient information: Achalasia (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?9/17/9491?source=see_link\">",
"     Patient information: Esophageal cancer (The Basics)",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11443904\">",
"    <span class=\"h3\">",
"     Beyond the Basics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?21/0/21506?source=see_link\">",
"     Patient information: Upper endoscopy (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?37/30/38373?source=see_link\">",
"     Patient information: Acid reflux (gastroesophageal reflux disease) in adults (Beyond the Basics)",
"    </a>",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Professional level information",
"    </span>",
"    &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"   </p>",
"   <p>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/26/14759?source=see_link\">",
"     Clinical manifestations and diagnosis of achalasia",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/17/12569?source=see_link\">",
"     Evaluation of dysphagia in adults",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/39/18039?source=see_link\">",
"     Overview of the treatment of achalasia",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/7/43124?source=see_link\">",
"     Pathophysiology and etiology of achalasia",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/32/12810?source=see_link\">",
"     Pneumatic dilation and botulinum toxin injection for achalasia",
"    </a>",
"    <br/>",
"   </p>",
"   <p>",
"    The following organizations also provide reliable health information.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      National Library of Medicine",
"      <br/>",
"      <br/>",
"      (",
"      <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/ency/article/000267.htm\">",
"       www.nlm.nih.gov/medlineplus/ency/article/000267.htm",
"      </a>",
"      , available in Spanish)",
"     </li>",
"     <li>",
"      The Society of Surgery of the Alimentary Tract",
"      <br/>",
"      <br/>",
"      (",
"      <a class=\"external\" href=\"file://www.ssat.com/cgi-bin/achalasia.cgi\">",
"       www.ssat.com/cgi-bin/achalasia.cgi",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      The Society of Thoracic Surgeons",
"      <br/>",
"      <br/>",
"      (",
"      <a class=\"external\" href=\"file://www.sts.org/\">",
"       www.sts.org",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2934/abstract/1-7\">",
"     1-7",
"    </a>",
"    ]",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20365127\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The author and editors would like to thank Dr. Pankaj J Pasricha, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2934/abstract/1\">",
"      West RL, Hirsch DP, Bartelsman JF, et al. Long term results of pneumatic dilation in achalasia followed for more than 5 years. Am J Gastroenterol 2002; 97:1346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2934/abstract/2\">",
"      Spiess AE, Kahrilas PJ. Treating achalasia: from whalebone to laparoscope. JAMA 1998; 280:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2934/abstract/3\">",
"      Eckardt VF, Kanzler G, Westermeier T. Complications and their impact after pneumatic dilation for achalasia: prospective long-term follow-up study. Gastrointest Endosc 1997; 45:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2934/abstract/4\">",
"      Pasricha PJ, Ravich WJ, Hendrix TR, et al. Intrasphincteric botulinum toxin for the treatment of achalasia. N Engl J Med 1995; 332:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2934/abstract/5\">",
"      Vaezi MF, Richter JE. Diagnosis and management of achalasia. American College of Gastroenterology Practice Parameter Committee. Am J Gastroenterol 1999; 94:3406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2934/abstract/6\">",
"      Vela MF, Richter JE, Khandwala F, et al. The long-term efficacy of pneumatic dilatation and Heller myotomy for the treatment of achalasia. Clin Gastroenterol Hepatol 2006; 4:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2934/abstract/7\">",
"      Boeckxstaens GE. Achalasia. Best Pract Res Clin Gastroenterol 2007; 21:595.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1998 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-217.117.136.88-94DAD92080-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_55_2934=[""].join("\n");
var outline_f2_55_2934=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      ACHALASIA OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ACHALASIA CAUSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ACHALASIA SYMPTOMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ACHALASIA DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Chest x-rays",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Barium swallow test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Manometry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Endoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ACHALASIA TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Drug therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Balloon dilation (pneumatic dilatation)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Procedure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Success rate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Surgery (myotomy)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Success rate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Botulinum toxin injection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Procedure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Success rate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      LONG-TERM RISK OF ESOPHAGEAL CANCER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      ACHALASIA FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      WHERE TO GET MORE INFORMATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1804546013\">",
"      Patient level information",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11443878\">",
"      - The Basics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11443904\">",
"      - Beyond the Basics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Professional level information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20365127\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/1998\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PI/1998|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/28/8642\" title=\"figure 1\">",
"      GERD PI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/40/643\" title=\"figure 2\">",
"      Barium swallow PI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/45/40671\" title=\"figure 3\">",
"      Nissen fundoplication PI",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/26/14759?source=related_link\">",
"      Clinical manifestations and diagnosis of achalasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/17/12569?source=related_link\">",
"      Evaluation of dysphagia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/39/18039?source=related_link\">",
"      Overview of the treatment of achalasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/7/43124?source=related_link\">",
"      Pathophysiology and etiology of achalasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/50/20258?source=related_link\">",
"      Patient information: Achalasia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/30/38373?source=related_link\">",
"      Patient information: Acid reflux (gastroesophageal reflux disease) in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/17/9491?source=related_link\">",
"      Patient information: Esophageal cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/0/21506?source=related_link\">",
"      Patient information: Upper endoscopy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/32/12810?source=related_link\">",
"      Pneumatic dilation and botulinum toxin injection for achalasia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_55_2935="Ponatinib: Drug information";
var content_f2_55_2935=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ponatinib: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?2/7/2166?source=see_link\">",
"    see \"Ponatinib: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F15826141\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F15847938\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Iclusig&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F15826158\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Tyrosine Kinase Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F15838982\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Acute lymphoblastic leukemia (ALL), Philadelphia chromosome-positive (Ph+), resistant or intolerant to prior tyrosine kinase inhibitor therapy:",
"     </b>",
"     Adults: Oral: 45 mg once daily; continue until disease progression or unacceptable toxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Chronic myelogenous leukemia (CML; chronic, accelerated, or blast phase), resistant or intolerant to prior tyrosine kinase inhibitor therapy:",
"     </b>",
"     Adults: Oral: 45 mg once daily; continue until disease progression or unacceptable toxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Dosage adjustment for strong CYP3A inhibitors:",
"     </b>",
"     Reduce ponatinib dose to 30 mg once daily when administered with concomitant strong CYP3A inhibitors (eg, boceprevir, clarithromycin, conivaptan, grapefruit juice, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, voriconazole).",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F15838998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15838985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling (has not been studied); although renal excretion is not a major excretion route for ponatinib.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15838986\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Mild impairment (Child-Pugh class A): No dosage adjustment provided in manufacturer's labeling (has not been studied); however, hepatic elimination is the major route of ponatinib excretion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Moderate-to-severe impairment (Child-Pugh class B or C): Avoid use (unless potential benefit outweighs potential risk of overexposure).",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F15838983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Hematologic:",
"     </b>",
"     ANC &lt;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     or platelets &lt;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      First occurrence:",
"     </i>",
"     Interrupt therapy; upon recovery of ANC to &ge;1500/mm",
"     <sup>",
"      3",
"     </sup>",
"     and platelets to &ge;75,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , resume therapy at 45 mg daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Second occurrence:",
"     </i>",
"     Interrupt therapy; upon recovery of ANC to &ge;1500/mm",
"     <sup>",
"      3",
"     </sup>",
"     and platelets to &ge;75,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , resume therapy at a reduced dose of 30 mg daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Third occurrence:",
"     </i>",
"     Interrupt therapy; upon recovery of ANC to &ge;1500/mm",
"     <sup>",
"      3",
"     </sup>",
"     and platelets to &ge;75,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , resume therapy at a reduced dose of 15 mg daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Nonhematologic toxicity:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Hepatotoxicity:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     AST or ALT &gt;3 times ULN: If toxicity occurs at dose of 45 mg daily, interrupt therapy; upon recovery to &le;grade 1 (&lt;3 times ULN), resume therapy at 30 mg daily. If toxicity occurs at dose of 30 mg daily, interrupt therapy; upon recovery to &le;grade 1, resume therapy at 15 mg daily. If toxicity occurs at dose of 15 mg daily, discontinue therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     ALT or AST &ge;3 times ULN with bilirubin &gt;2 times ULN and alkaline phosphatase &lt;2 times ULN: Discontinue therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Ischemic reactions:",
"     </i>",
"     Interrupt therapy; do not resume ponatinib in the event of serious ischemic reactions unless the potential benefit of therapy outweighs the risk of recurrent ischemia and other treatment options are not available.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Pancreatitis and lipase elevations:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Asymptomatic grade 1 or 2 serum lipase elevation: Consider interrupting therapy or dose reduction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Asymptomatic grade 3 or 4 serum lipase elevation (&gt;2 times ULN) or asymptomatic radiologic pancreatitis (grade 2): If toxicity occurs at dose of 45 mg daily, interrupt therapy; upon recovery to &le;grade 1 (&lt;1.5 times ULN), resume therapy at a reduced dose of 30 mg daily. If toxicity occurs at dose of 30 mg daily, interrupt therapy; upon recovery to &le;grade 1, resume therapy at a reduced dose of 15 mg daily. If toxicity occurs at dose 15 mg daily, discontinue therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Symptomatic grade 3 pancreatitis: If toxicity occurs at dose of 45 mg daily, interrupt therapy; upon recovery of serum lipase elevation to &le;grade 1 and complete symptom resolution, resume therapy at a reduced dose of 30 mg daily. If toxicity occurs at dose of 30 mg daily, interrupt therapy; upon recovery of serum lipase elevation to &le;grade 1 and complete symptom resolution, resume therapy at a reduced dose of 15 mg daily. If toxicity occurs at dose of 15 mg daily, discontinue therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Grade 4 pancreatitis: Discontinue therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Other nonhematologic toxicities:",
"     </i>",
"     For serious reactions (other than ischemia), do not restart therapy until symptom resolution or unless the benefit of therapy outweighs the risk of recurrent toxicity.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F15839098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Iclusig&reg;: 15 mg, 45 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F15838169\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F15838167\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Patient access and support is available through the ARIAD PASS program. Information regarding program enrollment may be found at file://www.ariadpass.com/healthcare-professional or by calling 1-855-447-PASS (7277).",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F15838165\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM333534.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM333534.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F15838987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with or without food.  Swallow tablets whole (do not crush or dissolve).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (meets NIOSH, 2012 criteria)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F15826144\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Treatment of chronic myelogenous leukemia (CML) in chronic, accelerated, or blast phase that is resistant or intolerant to prior tyrosine kinase inhibitor therapy; treatment of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F15838162\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Ponatinib may be confused with axitinib, bosutinib, cabozantinib, crizotinib, dasatinib, imatinib, nilotinib, regorafenib, ruxolitinib, vemurafenib",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medical Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F15838338\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Hypertension (53% to 71%), peripheral edema (13% to 22%; grades 3/4: &le;1%), heart failure (6% to 15%; including ejection fraction decreased, pulmonary edema, cardiogenic shock, cardiopulmonary failure), arterial ischemia (3% to 13%; grades 3/4: &le;7%; including cardiac, cerebro-, and peripheral-vascular events)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Fatigue or weakness (31% to 39%), headache (25% to 39%), fever (23% to 32%), pain (6% to 16%), chills (7% to 13%), insomnia (7% to 12%), dizziness (3% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Rash (34% to 54%), dry skin (24% to 39%), cellulitis (&le;11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Glucose increased (58%), phosphorus decreased (57%), calcium decreased (52%), sodium decreased (29%), glucose decreased (24%), potassium decreased (16%), potassium increased (15%), bicarbonate decreased (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Abdominal pain (34% to 49%), constipation (24% to 47%), lipase increased (41%; grades 3/4: 15%), nausea (22% to 32%), appetite decreased (8% to 31%), diarrhea (13% to 26%), vomiting (13% to 24%), oral mucositis (9% to 23%), weight loss (5% to 13%), gastrointestinal hemorrhage (2% to 11%; grades 3/4: &le;6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Genitourinary: Urinary tract infection (&le;12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Neutropenia (grades 3/4: 24% to 63%), leukopenia (grades 3/4: 14% to 63%), thrombocytopenia (grades 3/4: 36% to 57%), anemia (grades 3/4: 9% to 55%), lymphopenia (grades 3/4: 10% to 37%), neutropenic fever (1% to 25%), hemorrhage (24%; grades 3/4: 4% to 5%; including cerebral and gastrointestinal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: ALT increased (53%; grades 3/4: 8%), AST increased (41%; grades 3/4: 4%), alkaline phosphatase increased (37%), albumin decreased (28%), bilirubin increased (19%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Arthralgia (13% to 31%), myalgia (6% to 22%), limb pain (9% to 17%), back pain (11% to 16%), peripheral neuropathy (6% to 13%), muscle spasm (5% to 13%), bone pain (9% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Dyspnea (6% to 21%), pleural effusion (3% to 19%; grades 3/4: &le;3%), cough (6% to 18%), pneumonia (3% to 13%), nasopharyngitis (3% to 12%), upper respiratory tract infection (&le;11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Sepsis (1% to 22%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Myocardial infarction or other cardiac ischemic event (5%), supraventricular tachyarrhythmia (5%), atrial fibrillation (4%), venous thromboembolism (3%; including deep vein thrombosis, pulmonary embolism, portal vein thrombosis, and retinal vein thrombosis), pericardial effusion (1% to 3%), cerebral hemorrhage (2%), peripheral ischemia (2%), stroke or TIA (2%), bradyarrhythmia (1%; symptomatic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Sodium increased (10%), hyperuricemia (7%), calcium increased (5%), triglycerides increased (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Pancreatitis (6%; grade 3: 5%), amylase increased (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Renal: Creatinine increased (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Ascites, atrial flutter, atrial tachycardia, cerebral edema, gastrointestinal fistula, gastrointestinal perforation, heart block (complete), hepatic failure, sick sinus syndrome, supraventricular tachycardia, tumor lysis syndrome",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F15838178\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed in the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F15838179\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression: Severe myelosuppression (grade 3 or 4) was commonly observed in clinical trials, and the incidence was greater in patients with accelerated or blast phase CML and Ph+ ALL. Monitor blood counts closely; may require dosage reduction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fluid retention/edema: Serious fluid retention events, including one fatality due to brain edema (very rare), were observed in ponatinib-treated patients. Peripheral edema, pleural effusions, and pericardial effusions were commonly seen; effusions and ascites were less common. Monitor patients for fluid retention; may require therapy interruption, dosage reduction, or discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal perforation: Serious gastrointestinal perforation (fistula) occurred very rarely; monitor for signs/symptoms of perforation and/or fistula.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart failure/cardiac effects: Serious heart failure (HF) or left ventricular dysfunction, including fatalities, were reported in clinical trials. Monitor for signs/symptoms of HF; interrupt ponatinib therapy and treat as clinically warranted if HF develops. Consider ponatinib discontinuation in the event of serious HF. In addition, cardiac arrhythmias (bradyarrhythmias and tachyarrhythmias) occurred. Symptomatic bradyarrhythmia which required pacemaker implantation occurred in a few patients; other rhythms identified were complete heart block, sick sinus syndrome, and atrial fibrillation with bradycardia and pauses. Tacharrhythmias reported include atrial fibrillation, atrial flutter, supraventricular tachycardia, and atrial tachycardia; some events required hospitalization. Monitor for sign/symptoms of bradycardia (fainting, dizziness, chest pain) and tachycardia (palpitations, dizziness).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hemorrhage: Hemorrhagic events occurred commonly in ponatinib-treated patients, including serious events such as cerebral and gastrointestinal hemorrhages; fatalities were reported. Serious bleeding episodes occurred more frequently in patients with accelerated or blast phase CML, and Ph+ ALL; most patients had grade 4 thrombocytopenia. Monitor platelet levels closely and for signs/symptoms of bleeding, and interrupt therapy if necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxicity:",
"     <b>",
"      [U.S. Boxed Warning]: Liver failure and death resulting from ponatinib-induced hepatotoxicity were observed; monitor liver function prior to and at least monthly (or as clinically indicated) during treatment. Hepatotoxicity may require treatment interruption (followed by dose reduction) or discontinuation. One case of fulminant hepatic failure leading to death occurred within 1 week of therapy initiation;",
"     </b>",
"     acute liver failure has also occurred. Treatment may result in ALT and/or AST elevations, and may be irreversible.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertension: Treatment-emergent hypertension developed in over half of ponatinib-treated patients; symptomatic hypertension or hypertensive crisis were reported in several patients, requiring urgent intervention. Monitor blood pressure closely, and manage elevated pressures as clinically indicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pancreatitis: Treatment-related lipase elevations and clinical pancreatitis occurred in clinical studies; the majority of cases resolved within 2 weeks of therapy interruption or dose reduction. Monitor serum lipase every 2 weeks for the first 2 months and monthly thereafter or as clinically indicated; more frequent monitoring may be considered in patients with a history of pancreatitis or alcohol abuse. Monitor for clinical signs of pancreatitis, such as abdominal symptoms; interrupt therapy if necessary. Do not reinitiate treatment until complete resolution of symptoms and lipase level is &lt;1.5 times ULN.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thromboembolism:",
"     <b>",
"      [U.S. Boxed Warning]: Cardiovascular, cerebrovascular, and peripheral vascular arterial thrombosis, including fatal myocardial infarction (MI) and stroke events, have occurred. Interrupt treatment and consider discontinuation if arterial thrombotic events develop.",
"     </b>",
"     Many patients required a revascularization procedure due to serious arterial thrombosis. MI was the most common thrombosis event; most patients had 1 or more cardiovascular risk factors. Peripheral arterial events (digital or distal extremity necrosis) occurred (rarely) in patients with diabetes or peripheral arterial disease. Venous thromboembolism, including deep vein thrombosis, pulmonary embolism, portal vein and retinal vein thrombosis, occurred less frequently. Monitor for signs/symptoms of arterial or venous thromboembolism;",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tumor lysis syndrome: Hyperuricemia and serious tumor lysis syndrome (rare) were reported. Patients should receive adequate hydration and be monitored for elevated uric acid levels and/or the development of tumor lysis syndrome.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Wound healing impairment: As ponatinib inhibits VEGF activity, therapy may impair wound healing. Hold therapy for at least 1 week prior to major surgery; resume therapy post procedure based on clinical judgment of appropriate wound healing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Patients with 1 or more cardiovascular risk factors (eg, MI, coronary artery disease, angina, stroke, transient ischemic attack, hypertension, diabetes mellitus, hyperlipidemia, and smoking) may be at increased risk for arterial thrombosis when treated with ponatinib. Monitor for signs/symptoms of thrombosis; interrupt therapy and consider discontinuation if thrombosis occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: While ponatinib has not been studied in patients with hepatic impairment, it is metabolized and eliminated primarily through hepatic mechanisms; increased drug exposure (and increased adverse reactions) would be expected in patients with hepatic dysfunction. Avoid use in patients with moderate to severe (Child Pugh class B or C) impairment unless the benefit of therapy outweighs the risk of toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; High potential for interactions: When administering with strong CYP3A inhibitors, the ponatinib dose should be reduced. Concomitant therapy with strong CYP3A inducers should be avoided if possible.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drugs that elevate gastric pH: Elevated gastric pH may reduce ponatinib bioavailability; if possible, avoid concomitant use with proton pump inhibitors, H",
"     <sub>",
"      2",
"     </sub>",
"     blockers, or antacids.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Patients &ge;65 years of age may be more likely to experience weakness, decreased appetite, dyspnea, increased lipase, muscle spasms, peripheral edema, and thrombocytopenia; monitor closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (meets NIOSH, 2012 criteria)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F15896924\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of BCRP, CYP2C8 (minor), CYP2D6 (minor), CYP3A4 (minor), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     BCRP, P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F15896922\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the serum concentration of Ponatinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Antineoplastic Agents may decrease the absorption of Cardiac Glycosides. This may only affect digoxin tablets.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Digitoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May decrease the serum concentration of Ponatinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Ponatinib. Management: Per ponatinib U.S. prescribing information, the starting dose of ponatinib should be reduced to 30 mg daily during treatment with any strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May increase the serum concentration of Ponatinib. Management: Reduce ponatinib starting dose to 30 mg daily when patients consume grapefruit consistently or in large amounts. Since grapefruit effects on CYP3A mediated metabolism are variable and poorly predictable, consider advising patients to avoid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     H2-Antagonists: May decrease the serum concentration of Ponatinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May decrease the serum concentration of Ponatinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May decrease the serum concentration of Ponatinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Antineoplastic Agents may enhance the anticoagulant effect of Vitamin K Antagonists. Antineoplastic Agents may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F15838171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F15838172\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal reproduction studies when administered in doses lower than or equivalent to the normal human dose. Based on its mechanism of action, adverse effects on pregnancy would be expected. Women of childbearing potential should be advised to avoid pregnancy during therapy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F15838173\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F15838174\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The decision to discontinue ponatinib or discontinue breast-feeding during therapy should take into account the benefits of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F15838989\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken without regard to food. Avoid grapefruit juice.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16570463\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Iclusig Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg (60): $11496.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     45 mg (30): $11496.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F15838990\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential and platelets every 2 weeks for the first 3 months, then monthly or as clinically needed; liver function tests at baseline and at least monthly thereafter or more frequently if clinically warranted; serum lipase every 2 weeks for the first 2 months and monthly thereafter (more frequently in patients with a history of pancreatitis or alcohol abuse); serum electrolytes and uric acid; monitor cardiac function, blood pressure, signs/symptoms of thromboembolism, hemorrhage, fluid retention, pancreatitis (clinical signs), gastrointestinal perforation/fistula",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F15838242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ponatinib is a pan-BCR-ABL tyrosine kinase inhibitor with",
"     <i>",
"      in vitro",
"     </i>",
"     activity against cells expressing native or mutant BCR-ABL (including T315I); it also inhibits VEGFR, FGFR, PDGFR, FGFR, EPH, and SRC kinases, as well as KIT, RET, TIE2, and FLT3.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F15838264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Plasma concentrations not affected by food",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 1223 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: &gt;99% to plasma proteins",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Primarily hepatic through CYP3A4; CYP2C8, CYP2D6, and CYP3A5 are also involved in metabolism. Phase II metabolism occurs via esterases and/or amidases.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: May be reduced with a higher gastric pH",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: ~24 hours (range: 12-66 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak: &le;6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Feces (87%); urine (~5%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Cortes JE, Kantarjian H, Shah NP, et al, &ldquo;Ponatinib in Refractory Philadelphia Chromosome-Positive Leukemias,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2012, 367(22):2075-88.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/55/2935/abstract-text/23190221/pubmed\" id=\"23190221\" target=\"_blank\">",
"        23190221",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shah NP, &ldquo;Ponatinib: Targeting the T315I Mutation in Chronic Myelogenous Leukemia,&rdquo;",
"      <i>",
"       Clin Adv Hematol Oncol",
"      </i>",
"      , 2011, 9(12):925-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/55/2935/abstract-text/22252660/pubmed\" id=\"22252660\" target=\"_blank\">",
"        22252660",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zirm E, Spies-Weisshart B, Heidel F, et al, &ldquo;Ponatinib May Overcome Resistance of FLT3-ITD Harbouring Additional Point Mutations, Notably the Previously Refractory F691I Mutation,&rdquo;",
"      <i>",
"       Br J Haematol",
"      </i>",
"      , 2012, 157(4):483-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/55/2935/abstract-text/22409268/pubmed\" id=\"22409268\" target=\"_blank\">",
"        22409268",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 87456 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-806F72AFFC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_55_2935=[""].join("\n");
var outline_f2_55_2935=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15826141\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15847938\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15826158\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15838982\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15838998\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15838985\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15838986\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15838983\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15839098\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15838169\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15838167\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15838165\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15838987\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15826144\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15838162\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15838338\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15838178\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15838179\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15896924\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15896922\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15838171\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15838172\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15838173\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15838174\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15838989\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16570463\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15838990\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15838242\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15838264\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/87456\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/87456|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?2/7/2166?source=related_link\">",
"      Ponatinib: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_55_2936="Clinical management of substance dependence across the continuum of care";
var content_f2_55_2936=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical management of substance dependence across the continuum of care",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/55/2936/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/55/2936/contributors\">",
"     Karen Hartwell, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/55/2936/contributors\">",
"     Kathleen Brady, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/55/2936/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/55/2936/contributors\">",
"     Richard Saitz, MD, MPH, FACP, FASAM",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/55/2936/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/55/2936/contributors\">",
"     Richard Hermann, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/55/2936/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with chronic or relapsing substance dependence make up 40 to 60 percent of individuals receiving care for substance use disorders (SUD) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2936/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. These patients typically have marked impairments in functioning and high rates of co-occurring medical and mental health problems. They tend to present for episodic treatment at points of high acuity and experience gaps in treatment over time, incurring substantial costs to themselves and society.",
"   </p>",
"   <p>",
"    This topic describes the clinical management of chronic or relapsing substance dependence, with an emphasis on care over time and across the tiered system of services in the United States (US) known as the continuum of care.",
"   </p>",
"   <p>",
"    Care for specific substances and specific treatments for substance dependence are described in detail elsewhere.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/58/5033?source=see_link\">",
"       \"Substance use disorders: Principles for recognition and assessment in general medical care\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/61/20441?source=see_link\">",
"       \"Management of moderate and severe alcohol withdrawal syndromes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/16/4361?source=see_link\">",
"       \"Ambulatory alcohol detoxification\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41847?source=see_link\">",
"       \"Psychosocial treatment of alcohol abuse and dependence\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19209?source=see_link\">",
"       \"Pharmacotherapy for alcohol abuse and dependence\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/12/32970?source=see_link\">",
"       \"Cocaine abuse and dependence in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/10/1191?source=see_link\">",
"       \"Opioid detoxification during treatment for addiction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/52/29514?source=see_link\">",
"       \"Treatment of opioid abuse and dependence\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/28/4554?source=see_link\">",
"       \"Cannabis use disorders: Treatment, prognosis, and long-term medical effects\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/27/3514?source=see_link\">",
"       \"Gamma hydroxybutyrate (GHB) dependence and withdrawal\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CHRONIC DISEASE MODEL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accumulating evidence supports the application of the chronic disease model to a significant proportion of individuals with substance dependence [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2936/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Studies have found that 40 to 60 percent of patients treated for alcohol or other drug dependence return to active use within a year following treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2936/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Despite the development of efficacious and well-tolerated medications for the treatment of nicotine, alcohol, and opioid dependence, there is considerable room for the development of new treatments.",
"   </p>",
"   <p>",
"    Periods of problematic use and associated functional impairment often occur for many years after diagnostic criteria for dependence are met [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2936/abstract/6\">",
"     6",
"    </a>",
"    ]. The conceptualization of substance dependence as a chronic disease is supported by comparison of its diagnostic criteria, etiologic factors (genetic and environmental), pathophysiology, and response to treatment with other chronic medical illnesses (eg, type II diabetes mellitus, asthma, and hypertension) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2936/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Substance abuse and dependence have been found to cause predictable and persistent structural and functional changes in the brain. Volume loss of numerous types of brain tissue and structures has been found in alcohol dependence [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2936/abstract/7,8\">",
"     7,8",
"    </a>",
"    ], cocaine dependence [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2936/abstract/9\">",
"     9",
"    </a>",
"    ], opiate dependence [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2936/abstract/10\">",
"     10",
"    </a>",
"    ], and polysubstance abuse [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2936/abstract/11\">",
"     11",
"    </a>",
"    ]. Longitudinal studies of individuals with alcohol dependence suggest there may be some improvement following treatment and sustained abstinence [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2936/abstract/12\">",
"     12",
"    </a>",
"    ]. Numerous neurotransmitter systems involved in reward and stress pathways in the brain are affected by chronic use of alcohol and other drugs, including dopamine and endogenous endorphins [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2936/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The conceptualization of substance dependence as a chronic disease has important implications for clinical management. Life-long treatment is an expectation for chronic medical diseases such as asthma and diabetes. Historically, however, SUD treatment has tended to focus on acute episodes of care, which are time-limited and carry an unrealistic expectation of enduring outcomes. This runs counter to studies of the course of substance dependence. Patients with chronic or relapsing substance dependence need sustained clinical management over the long term, with modifications in intensity as the illness waxes and wanes over time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CONTINUUM OF CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The \"continuum of care\" model for SUD services was established initially in the US public sector and later adopted by private systems of care, and embedded in the payment model for SUD care in the US.",
"   </p>",
"   <p>",
"    The continuum of care consists of several tiers of clinical services varying by setting, types of treatment, and intensity of treatment. Standard levels of care for SUD include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Inpatient care",
"     </li>",
"     <li>",
"      Residential care",
"     </li>",
"     <li>",
"      Partial hospital care",
"     </li>",
"     <li>",
"      Intensive outpatient care",
"     </li>",
"     <li>",
"      Outpatient care",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Services range from the most intensive, inpatient care, to the least intensive, infrequent outpatient encounters. Intensity is reflected in the number of hours of treatment per week, the number of clinical disciplines involved, the degree of patient supervision versus autonomy, and the number of services provided. Treatment is said to be \"stepped down\" when a patient is transferred from a higher to lower level of care. Treatment is most commonly \"stepped up\" when a patient relapses or the current level of care proves inadequate.",
"   </p>",
"   <p>",
"    Patients are assigned based on clinical assessment to a level of care that is consistent with their phase of illness and clinical status. Numerous \"level of care criteria\" have been developed to guide this matching process. Among the most clinically detailed and widely used are the American Society of Addiction Medicine's Patient Placement Criteria, Second Edition [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2936/abstract/15\">",
"     15",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"local\" href=\"#H4\">",
"     'Patient placement'",
"    </a>",
"    below). There have been few clinical trials of the relationship between matching patients to levels of care and SUD outcomes, and findings have been mixed [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2936/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATIENT PLACEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The determination of a patient's level of care should be made by a clinician familiar with services available and based on careful, individualized assessment of the patient. Domains of assessment are listed below, illustrated in the figure, and applied in the descriptions of specific levels of care that follow [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2936/abstract/15\">",
"     15",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"graphic graphic_algorithm graphicRef78806 \" href=\"UTD.htm?26/23/27007\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      SUD diagnosis",
"     </li>",
"     <li>",
"      Current intoxication",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      withdrawal potential",
"     </li>",
"     <li>",
"      Active medical conditions or complications",
"     </li>",
"     <li>",
"      Patient's readiness to change",
"     </li>",
"     <li>",
"      Substance-use status: relapse, current use, risk of use",
"     </li>",
"     <li>",
"      Active psychiatric conditions or complications",
"     </li>",
"     <li>",
"      Home environment's supportiveness of recovery",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     LEVELS OF CARE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Inpatient care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inpatient care mainly provides detoxification for substance-dependent individuals over brief lengths of stay (eg, two to five days). Detoxification consists of supervised withdrawal from the substance with medication to diminish the withdrawal symptoms. Substances with withdrawal syndromes that can be effectively treated include alcohol, benzodiazepines, other",
"    <span class=\"nowrap\">",
"     sedatives/hypnotics,",
"    </span>",
"    and opiates. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/61/20441?source=see_link\">",
"     \"Management of moderate and severe alcohol withdrawal syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/10/1191?source=see_link\">",
"     \"Opioid detoxification during treatment for addiction\"",
"    </a>",
"    .) Cessation of cocaine, amphetamines, and marijuana can be followed by withdrawal symptoms, but absent other medical complications, there are no established treatment protocols for these symptoms.",
"   </p>",
"   <p>",
"    Inpatient detoxification takes place either in free-standing treatment centers or, for medically complicated patients, in hospitals. Inpatient programs usually include group treatment that provides education and support. Medication to prevent relapse may be started during an inpatient stay.",
"   </p>",
"   <p>",
"    Until recent years, inpatient stays were often longer and included both detoxification and rehabilitation (ie, psychosocial treatment focused on preventing relapse). Clinical trials demonstrated that selected populations could be treated at lower, less resource-intensive levels of care [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2936/abstract/18\">",
"     18",
"    </a>",
"    ], reserving inpatient treatment for more severe and complicated detoxification and for patients with significant comorbid medical and psychiatric problems. Today, far fewer patients receive inpatient rehabilitation. More commonly, this phase of treatment is received at a lower level of care following inpatient discharge.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Residential care",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a wide range of public and private-sector residential programs for substance dependence. All provide a 24-hour, drug and alcohol-free environment, along with professional or peer support. Residential care addresses those aspects of patients' prior living environment that contribute to their potential for relapse.",
"   </p>",
"   <p>",
"    The decision to admit a patient to a residential program requires assessment of the patient's readiness to change. In contrast to other levels of care, these programs require a commitment to maintaining abstinence.",
"   </p>",
"   <p>",
"    Shorter-term programs are intended to provide transitional support, eg, between inpatient detoxification and independent living, while other programs provide a long-term residence. Programs vary greatly in their staffing, the degree to which treatment is provided, the types of treatment, and their underlying philosophy. Three widely used residential programs are described below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Community residential treatment facilities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Community residential treatment facilities (CRFs) provide transitional housing and treatment, often following inpatient detoxification. The cost of CRF treatment often must be borne by the patient, though funded CRF services may be available through Medicaid programs in some states, through some private payers, and for selected populations (eg, veterans using Veterans Administration services). Lengths of stay vary, but are on the order of weeks to a few months. CRFs themselves vary in their services and philosophy. Three distinct models have been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2936/abstract/19\">",
"     19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Psychosocial model &mdash; These residential programs primarily provide psychosocial services such as individual and group therapy, social skills training, and self-help groups.",
"     </li>",
"     <li>",
"      Supportive rehabilitative&nbsp;model &mdash; In addition to psychosocial services, these programs provide work training and more specialized services such as recreational and occupational therapy.",
"     </li>",
"     <li>",
"      Intensive treatment&nbsp;model &mdash; In addition to the services above, these programs provide medical and psychiatric services, including medication treatment, couples and family counseling, and nutrition counseling.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Observational studies have described CRF residents as well as resident and program characteristics associated with better outcomes. In one large observational study, CRF residents had high rates of unemployment, social isolation, and prior SUD treatment. About 40 percent had a concomitant psychiatric illness [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2936/abstract/20\">",
"     20",
"    </a>",
"    ]. In another study of approximately 2800 residents from a nationally representative sample of 88 CRFs, greater motivation for treatment, social and personal resources, and prior involvement with self-help groups were associated with better outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2936/abstract/21\">",
"     21",
"    </a>",
"    ]. More severe SUDs and co-morbid psychiatric problems were associated with worse outcomes. A third study found that CRFs with a more structured approach to treatment had better retention rates and SUD outcomes than programs with a more generic approach [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2936/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Therapeutic communities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapeutic communities (TCs) traditionally provide residential care for substance-dependent individuals, though the model has been applied to other levels of care and clinical conditions as well. The programs are highly structured, provide comprehensive services, and are based on an explicit set of principles, including a focus on the community as a means of facilitating individual change [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2936/abstract/23\">",
"     23",
"    </a>",
"    ]. Treatment goals include changes in identity and lifestyle, including abstinence from substances, employment, cessation of antisocial behavior, and prosocial values. Lengths of stay are typically between 15 to 24 months. Most patients who enter TC have extensive substance-use histories and significant psychosocial dysfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Oxford house",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oxford House is a non-profit network of 1200 houses across the US for individuals recovering from substance dependence (",
"    <a class=\"external\" href=\"file://www.oxfordhouse.org/\">",
"     www.oxfordhouse.org",
"    </a>",
"    ). Each house is rented, financially self-supporting, and drug free. Residents live without professional staff or length of stay restrictions, and are free to choose treatment of any type if they wish. In a randomized trial, 150 patients discharged after SUD treatment were assigned to either an Oxford house or treatment as usual. After 24 months, participants living in an Oxford house had a lower rate of relapse (46 versus 65 percent), higher monthly income, and lower incarceration rates compared with the control group [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2936/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Partial hospital programs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Partial hospital programs (PHP) provide a structured, intensive non-residential program. By some definitions, PHPs have at least 20 hours of treatment per week, including individual and group counseling, medication management, educational groups, and other services such as occupational therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2936/abstract/15\">",
"     15",
"    </a>",
"    ]. Treatment goals are to attain or maintain sobriety, improve functioning, and maintain residence in the community.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Intensive outpatient programs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intensive outpatient programs (IOPs) offer intensive services similar to those of partial hospital programs, but for less time each week. Patients typically participate for 10 to 20 hours per week. IOPs and PHPs are often provided by the same staff, share the same modalities and treatment goals, and may consist of the same programming, with IOP patients attending less frequently. The services typically include individual and group counseling, medication management, and educational groups [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2936/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Outpatient care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with substance dependence selectively use some of the same services that are aggregated into PHPs and IOPs. Typically, they attend one or more individual",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    group counseling sessions, and may have visits to a physician for medication treatment for substance dependence. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41847?source=see_link\">",
"     \"Psychosocial treatment of alcohol abuse and dependence\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19209?source=see_link\">",
"     \"Pharmacotherapy for alcohol abuse and dependence\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/52/29514?source=see_link\">",
"     \"Treatment of opioid abuse and dependence\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Self-help groups such as Alcoholics Anonymous or SMART Recovery are often a component of outpatient treatment, and may be integrated into higher levels of care as well. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41847?source=see_link&amp;anchor=H12#H12\">",
"     \"Psychosocial treatment of alcohol abuse and dependence\", section on 'Peer support groups'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Detoxification can be provided on an outpatient basis for patients with mild to moderate withdrawal symptoms, a supportive living situation, and the absence of comorbidities or other complications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/16/4361?source=see_link\">",
"     \"Ambulatory alcohol detoxification\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/10/1191?source=see_link\">",
"     \"Opioid detoxification during treatment for addiction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Influence of co-occurring conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;SUDs are accompanied by high rates of mental disorders and medical conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2936/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/58/5033?source=see_link\">",
"     \"Substance use disorders: Principles for recognition and assessment in general medical care\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36521?source=see_link\">",
"     \"Dual diagnosis: Severe mental illness and substance use disorders\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/24/25993?source=see_link\">",
"     \"Screening for unhealthy use of alcohol and other drugs\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    SUD-treatment programs vary markedly in their capacity to treat these comorbidities. Some do not accept patients with active mental disorders or medical conditions. Other programs do not have staff capable of treating these conditions but permit patients to receive concurrent medical or psychiatric care outside the program. Many partial-hospital, and intensive-outpatient programs provide psychiatric",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    medical treatment as an integral part of their program. Some systems of care have integrated programs at each level of care for treatment of dual diagnoses (ie, individuals with an SUD and mental disorder).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     CONTINUING CLINICAL MANAGEMENT",
"    </span>",
"   </p>",
"   <p>",
"    Despite the increasing recognition of substance dependence as a chronic illness, continuity of care across levels of care and over time remains limited. Much of SUD care in the US is time-limited and focused on acute episodes. Findings from a national survey of outpatient SUD treatment programs found that the planned duration of outpatient care was most often 90 days, while the actual duration was less than 30 days [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2936/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies of continuing clinical management following attainment of abstinence and completion of formal treatment have shown promising results [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2936/abstract/5,28-30\">",
"     5,28-30",
"    </a>",
"    ]. A randomized trial assessed the impact of \"recovery management checkups\" in a study of 448 adults with a SUD. Subjects in the intervention group were evaluated by a clinician every three months for two years. If they had an active disorder, subjects were referred to treatment and encouraged to follow through. Compared with a control group that received evaluation only, those receiving standardized checkups were more likely to receive treatment, obtain treatment earlier, and had better substance use outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2936/abstract/27\">",
"     27",
"    </a>",
"    ]. Another randomized trial evaluated a brief intervention for heavy drinking in primary care that was followed by four years of monthly visits and feedback from laboratory testing. Compared with a control group that received usual care, the intervention group did better on some but not all clinical outcomes over a six-year follow-up period [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2936/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinicians seeking to provide continuing management often face obstacles, including insufficient program funding, absence of reimbursement for telephone-based care, inadequate reimbursement for post-abstinence monitoring visits, and gaps or long waiting lists for services within a locality's continuum of care. In addition, many patients with substance dependence fail to follow treatment recommendations or drop out of programs altogether [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2936/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When feasible, we suggest that patients with chronic or relapsing substance dependence receive continuing clinical management. Principles to guide this practice are listed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Ongoing clinical relationship",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with chronic or relapsing substance dependence should have a continuing relationship with a clinician primarily responsible for SUD treatment or coordinating the patient's care. This may be the patient's primary care clinician, substance abuse counselor, psychiatrist, case manager, or other clinician, depending on the system structure and resources as well as the patient's treatment history.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Regular reassessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;During active treatment, the clinician should reassess the patient's clinical status at regular intervals, with subsequent determination of whether a change in level of care is indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Monitoring after active treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest maintaining clinical contact with patients with chronic or relapsing substance dependence after abstinence has been achieved and treatment traditionally ends. At each encounter, the clinician should reassess the patient's clinical status and provide encouragement, support, or facilitate the resumption of treatment, as indicated. Research studies have not adequately determined the effectiveness of this practice, or the type or frequency of the encounters [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2936/abstract/5,28-30\">",
"     5,28-30",
"    </a>",
"    ]. Options that have been tested include telephone and face-to-face encounters at frequencies of monthly to every three months during the first two years. After two years of abstinence, annual checkups could be considered a minimal level of monitoring.",
"   </p>",
"   <p>",
"    As with other chronic conditions, recurrence of active substance abuse is common among individuals with substance dependence. Relapse can be viewed as providing opportunities for learning how to maintain abstinence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Care for co-occuring conditions",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinicians treating a patient for substance dependence should periodically screen the patient for mental disorders and, if a disorder is suspected, refer the patient for psychiatric assessment. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36521?source=see_link&amp;anchor=H10#H10\">",
"       \"Dual diagnosis: Severe mental illness and substance use disorders\", section on 'Screening'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The clinician should strongly urge patients to obtain routine primary care and adhere to resulting treatment recommendations.",
"     </li>",
"     <li>",
"      Clinicians providing either SUD, psychiatric, or medical care should routinely communicate with one another relevant information on changes in the patient's clinical status and treatment. State laws vary with regard to the need for the patient's consent to communicate, though informed consent is preferable.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Participation in self-help groups",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians should encourage patients to maintain ongoing participation in self-help programs even after sustained abstinence is achieved. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41847?source=see_link&amp;anchor=H12#H12\">",
"     \"Psychosocial treatment of alcohol abuse and dependence\", section on 'Peer support groups'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Relapse prevention plan",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients who complete active treatment should have a relapse prevention plan that documents potential triggers and early warning signs, along with strategies to respond. The plan should name sponsors, family members, or friends who have agreed to help, in addition to clinicians' contact information.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Case management",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some systems of care, case management services are provided to coordinate care for patients with SUDs. Case management is a set of social services that help patients access resources necessary for recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2936/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Case managers focus on obtaining resources rather than in internal changes typical of therapy or counseling. Models of case management can vary in philosophy, methodology, and comprehensiveness, but usually include the following functions [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2936/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Coordinate multiple services, eg, care for SUD, mental disorders, and medical conditions as well as social services.",
"     </li>",
"     <li>",
"      Help patients to access psychosocial rehabilitation and social skills training to increase psychosocial functioning.",
"     </li>",
"     <li>",
"      Facilitate access to resources on employment, vocational training, housing, transportation, financial assistance, and other social services.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A meta-analysis of seven randomized trials with a total of 2391 patients with SUDs found that case management led to more patient linkages to treatment services but did not reduce substance use [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2936/abstract/34\">",
"     34",
"    </a>",
"    ]. Findings for other outcomes were inconclusive. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36521?source=see_link&amp;anchor=H21#H21\">",
"     \"Dual diagnosis: Severe mental illness and substance use disorders\", section on 'Psychosocial treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with chronic or relapsing substance dependence make up 40 to 60 percent of individuals receiving care for substance use disorders (SUD). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Chronic disease model'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      These patients often need sustained clinical management over the long term, with modifications in intensity as the illness waxes and wanes over time. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Chronic disease model'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the United States, treatment is provided via a continuum of care, ie, several tiers of clinical services varying by setting, types of treatment, and intensity. Standard levels of care include inpatient, residential, partial hospital, intensive outpatient, and outpatient care. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Continuum of care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      During active treatment, the clinician should reassess the patient's clinical status at regular intervals, with subsequent determination of whether a change in level of care is indicated.",
"     </li>",
"     <li>",
"      Factors influencing level-of-care assignment include the patient's diagnosis, status regarding substance use, intoxication, and withdrawal, presence of an active medical or psychiatric condition, readiness to change, and the supportiveness of the patient's home environment to maintaining abstinence. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Patient placement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that ongoing clinical contact be maintained with patients with chronic or relapsing substance dependence after abstinence has been achieved and formal treatment ends (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). As resources permit, these encounters can be conducted in individual or group sessions or by telephone, initially monthly and decreasing in frequency as abstinence continues. At each encounter, the clinician should assess the patient's clinical status, provide encouragement and support, assist with problem solving, and initiate resumption of active treatment, as indicated. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Continuing clinical management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that clinicians strongly encourage patients to maintain ongoing participation in self-help groups (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Continuing clinical management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;This work was supported in part by the Ralph H Johnson VAMC.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2936/abstract/1\">",
"      Finney JW, Moos RH. The long-term course of treated alcoholism: II. Predictors and correlates of 10-year functioning and mortality. J Stud Alcohol 1992; 53:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2936/abstract/2\">",
"      Hubbard RL, Craddock G, Flynn PM, et al. Overview of 1-year follow-up outcomes in the Drug Abuse Treatment Outcome Study (DATOS). Psychol Addict Behav 1997; 11:261.",
"     </a>",
"    </li>",
"    <li>",
"     McLellan AT, McKay J. The treatment of addiction: what can research offer practice? In: Bridging the Gap: Forging New Partnerships in Community-Based Drug Abuse Treatment, Lamb S, Greenlick M, McCarty D (Eds), National Academy Press, Washington, DC 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2936/abstract/4\">",
"      McLellan AT, Lewis DC, O'Brien CP, Kleber HD. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA 2000; 284:1689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2936/abstract/5\">",
"      McKay JR. Is there a case for extended interventions for alcohol and drug use disorders? Addiction 2005; 100:1594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2936/abstract/6\">",
"      Vaillant GE. A 60-year follow-up of alcoholic men. Addiction 2003; 98:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2936/abstract/7\">",
"      Nagel, BJ, Kroenke, CD. Technologies from the Field: The use of magnetic resonanace spectroscopy and magnetic resonance imaging in alcohol research. In: Neuroscience: Pathways to Alcohol Dependence-Part 1 Overview of the Neurobiology of Dependence 2009; 31:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2936/abstract/8\">",
"      Sullivan EV, Pfefferbaum A. Neurocircuitry in alcoholism: a substrate of disruption and repair. Psychopharmacology (Berl) 2005; 180:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2936/abstract/9\">",
"      Franklin TR, Acton PD, Maldjian JA, et al. Decreased gray matter concentration in the insular, orbitofrontal, cingulate, and temporal cortices of cocaine patients. Biol Psychiatry 2002; 51:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2936/abstract/10\">",
"      Lyoo IK, Pollack MH, Silveri MM, et al. Prefrontal and temporal gray matter density decreases in opiate dependence. Psychopharmacology (Berl) 2006; 184:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2936/abstract/11\">",
"      Liu X, Matochik JA, Cadet JL, London ED. Smaller volume of prefrontal lobe in polysubstance abusers: a magnetic resonance imaging study. Neuropsychopharmacology 1998; 18:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2936/abstract/12\">",
"      Cardenas VA, Studholme C, Gazdzinski S, et al. Deformation-based morphometry of brain changes in alcohol dependence and abstinence. Neuroimage 2007; 34:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2936/abstract/13\">",
"      Ulm, RR, Volpicelli,JR, Volpicelli, LA. Opiates and alcohol self-adminstration in animals. Journal of Clinical Psychiatry 1995; 56(suppl 7):5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2936/abstract/14\">",
"      Volkow ND, Fowler JS, Wang GJ, et al. Dopamine in drug abuse and addiction: results of imaging studies and treatment implications. Arch Neurol 2007; 64:1575.",
"     </a>",
"    </li>",
"    <li>",
"     Patient placement criteria for the treatment of substance-related disorders (ASAM PPC-2) 2nd ed, American Society of Addiction Medicine. Chevy Chase MD 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2936/abstract/16\">",
"      Gastfriend DR, McLellan AT. Treatment matching. Theoretic basis and practical implications. Med Clin North Am 1997; 81:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2936/abstract/17\">",
"      Chen S, Barnett PG, Sempel JM, Timko C. Outcomes and costs of matching the intensity of dual-diagnosis treatment to patients' symptom severity. J Subst Abuse Treat 2006; 31:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2936/abstract/18\">",
"      Hayahida, M, Alterman, AI, McLellan, AT, et al. Comparative effectiveness and costs of inpatient and outpatient detoxification of patients with mild-moderate alcohol withdrawal syndrome. N Eng J Med 1989; 320:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2936/abstract/19\">",
"      Moos RH, Pettit B, Gruber VA. Characteristics and outcomes of three models of community residential care for abuse patients. J Subst Abuse 1995; 7:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2936/abstract/20\">",
"      Moos RH, Moos BS. Stay in residential facilities and mental health care as predictors of readmission for patients with substance use disorders. Psychiatr Serv 1995; 46:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2936/abstract/21\">",
"      Moos RH, King MJ. Participation in community residential treatment and substance abuse patients' outcomes at discharge. J Subst Abuse Treat 1997; 14:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2936/abstract/22\">",
"      Moos RH, Moos BS, Andrassy JM. Outcomes of four treatment approaches in community residential programs for patients with substance use disorders. Psychiatr Serv 1999; 50:1577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2936/abstract/23\">",
"      De Leon G. Therapeutic communities for addictions: a theoretical framework. Int J Addict 1995; 30:1603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2936/abstract/24\">",
"      Jason LA, Olson BD, Ferrari JR, et al. An examination of main and interactive effects of substance abuse recovery housing on multiple indicators of adjustment. Addiction 2007; 102:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2936/abstract/25\">",
"      Narrow WE, Rae DS, Robins LN, Regier DA. Revised prevalence estimates of mental disorders in the United States: using a clinical significance criterion to reconcile 2 surveys' estimates. Arch Gen Psychiatry 2002; 59:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2936/abstract/26\">",
"      Cornelius JR, Reynolds M, Martz BM, et al. Premature mortality among males with substance use disorders. Addict Behav 2008; 33:156.",
"     </a>",
"    </li>",
"    <li>",
"     Substance Abuse and Mental Health Services Administration (SAMHSA). National survey of substance abuse treatment: Data for 2000-2001. DHHS Publication No. SMA 98-3176. Washington, DC 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2936/abstract/28\">",
"      Dennis, M. An experimental evaluation of recovery management checkups (RMC) for people with chronic substance use disorders. Eval Program Plann 2003; 26:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2936/abstract/29\">",
"      Kristenson H, Osterling A, Nilsson JA, Lindg&auml;rde F. Prevention of alcohol-related deaths in middle-aged heavy drinkers. Alcohol Clin Exp Res 2002; 26:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2936/abstract/30\">",
"      Hilton ME, Maisto SA, Conigliaro J, et al. Improving alcoholism treatment across the spectrum of services. Alcohol Clin Exp Res 2001; 25:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2936/abstract/31\">",
"      Olfson M, Mojtabai R, Sampson NA, et al. Dropout from outpatient mental health care in the United States. Psychiatr Serv 2009; 60:898.",
"     </a>",
"    </li>",
"    <li>",
"     JCAHO. Principles of Accreditation of Community Mental Health Service Programs. Joint Commission on Accreditation of Hospitals 1979.",
"    </li>",
"    <li>",
"     SAMSHA. Comprehensive Case Management for Substance Abuse Treatment. PHS, SAMSHSA, Center for Substance Abuse Treatment 1998.",
"    </li>",
"    <li>",
"     Hesse, M. Cochrane Database Syst Rev 2007:CD006265.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7799 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-6F4C19BDB0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_55_2936=[""].join("\n");
var outline_f2_55_2936=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CHRONIC DISEASE MODEL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CONTINUUM OF CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATIENT PLACEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      LEVELS OF CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Inpatient care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Residential care",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Community residential treatment facilities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Therapeutic communities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Oxford house",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Partial hospital programs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Intensive outpatient programs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Outpatient care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Influence of co-occurring conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      CONTINUING CLINICAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Ongoing clinical relationship",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Regular reassessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Monitoring after active treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Care for co-occuring conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Participation in self-help groups",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Relapse prevention plan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Case management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/7799\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/7799|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?26/23/27007\" title=\"algorithm 1\">",
"      Level of care matching",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/16/4361?source=related_link\">",
"      Ambulatory alcohol detoxification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/28/4554?source=related_link\">",
"      Cannabis use disorders: Treatment, prognosis, and long-term medical effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/12/32970?source=related_link\">",
"      Cocaine abuse and dependence in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36521?source=related_link\">",
"      Dual diagnosis: Severe mental illness and substance use disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/27/3514?source=related_link\">",
"      Gamma hydroxybutyrate (GHB) dependence and withdrawal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/61/20441?source=related_link\">",
"      Management of moderate and severe alcohol withdrawal syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/10/1191?source=related_link\">",
"      Opioid detoxification during treatment for addiction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19209?source=related_link\">",
"      Pharmacotherapy for alcohol abuse and dependence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41847?source=related_link\">",
"      Psychosocial treatment of alcohol abuse and dependence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/24/25993?source=related_link\">",
"      Screening for unhealthy use of alcohol and other drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/58/5033?source=related_link\">",
"      Substance use disorders: Principles for recognition and assessment in general medical care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/52/29514?source=related_link\">",
"      Treatment of opioid abuse and dependence",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_55_2937="Treatment of endophthalmitis due to molds";
var content_f2_55_2937=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of endophthalmitis due to molds",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/55/2937/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/55/2937/contributors\">",
"     Marlene L Durand, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/55/2937/contributors\">",
"     Carol A Kauffman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/55/2937/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/55/2937/contributors\">",
"     Kieren A Marr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/55/2937/contributors\">",
"     Jonathan Trobe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/55/2937/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/55/2937/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/55/2937/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H634314692\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endophthalmitis due to molds is uncommon in temperate climates, but is common in tropical regions such as India. Fusarium and Aspergillus spp account for most cases of mold endophthalmitis. Mold endophthalmitis often results in loss of vision.",
"   </p>",
"   <p>",
"    The treatment of endophthalmitis due to molds will be reviewed here. The epidemiology, clinical features, and diagnosis of fungal endophthalmitis are discussed elsewhere. The treatment of endophthalmitis caused by Candida and bacterial species are also presented separately. Fusarium keratitis is also discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13849?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of fungal endophthalmitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/12/39112?source=see_link\">",
"     \"Treatment of endogenous endophthalmitis due to Candida species\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/16/36102?source=see_link\">",
"     \"Treatment of exogenous endophthalmitis due to Candida species\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/18/24873?source=see_link\">",
"     \"Bacterial endophthalmitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/42/3753?source=see_link&amp;anchor=H346085004#H346085004\">",
"     \"Treatment and prevention of Fusarium infection\", section on 'Keratitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H198244885\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term \"endophthalmitis\" means infection within the eye involving the vitreous",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    aqueous (",
"    <a class=\"graphic graphic_figure graphicRef57690 \" href=\"UTD.htm?41/35/42549\">",
"     figure 1",
"    </a>",
"    ).",
"    <br/>",
"    <br/>",
"    <strong>",
"     Endogenous endophthalmitis",
"    </strong>",
"    results from bacterial or fungal seeding of the eye via the bloodstream. In most cases of endogenous mold endophthalmitis, the highly vascular choroid is seeded first, and the infection typically progresses from the &ldquo;back&rdquo; of the eye (posterior segment) anteriorly.",
"    <br/>",
"    <br/>",
"    <strong>",
"     Exogenous endophthalmitis",
"    </strong>",
"    means the infection was introduced from the &ldquo;outside,&rdquo; for example, following eye surgery, eye trauma, or extension of fungal infection of the cornea (termed &ldquo;fungal keratitis&rdquo; or &ldquo;keratomycosis&rdquo;). In exogenous endophthalmitis, the aqueous is typically infected first, and in some cases, the vitreous is not involved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H634314713\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of mold endophthalmitis typically involves a combination of vitrectomy, intravitreal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    intracameral (into the anterior chamber) injection of an antifungal agent, removal of foreign materials (eg, intraocular lens), and systemic antifungal therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2937/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Corneal transplantation is indicated in some cases. No controlled trials of treatment regimens for mold endophthalmitis have been performed given its rarity. The evidence regarding the treatment of mold endophthalmitis comes from case reports and case series. Even with therapy, there is a high rate of loss of useful vision, but the prognosis may be improving with the availability of newer antifungal agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H234846856\">",
"     'Prognosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H365246849\">",
"    <span class=\"h2\">",
"     Vitrectomy and removal of foreign bodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical removal of the vitreous, or vitrectomy, is nearly always necessary in mold endophthalmitis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2937/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Vitrectomy entails the use of a vitrector, an instrument inserted into the vitreous cavity that simultaneously cuts and aspirates some of the approximately 4 mL of gel-like vitreous into a canister (",
"    <a class=\"graphic graphic_figure graphicRef59512 \" href=\"UTD.htm?30/11/30899\">",
"     figure 2",
"    </a>",
"    ). During this process, a separate cannula infuses",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/62/30690?source=see_link\">",
"     balanced salt solution",
"    </a>",
"    into the vitreous cavity to maintain intraocular pressure. By the end of the case, the canister contains dilute vitreous &ldquo;washings&rdquo; (eg, 50 to 100 mL). Vitrectomy decreases the burden of fungi quickly by debriding the vitreous [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2937/abstract/4\">",
"     4",
"    </a>",
"    ]. Samples are obtained during vitrectomy for microbiologic studies, and intravitreal antibiotics are injected at the end of the case. A vitrectomy may be difficult if there is so much inflammation that the retina surgeon cannot see the retina. The potential risk of this procedure (versus needle aspiration for culture followed by intravitreal antibiotic injection) must be balanced by the potential benefit of adequate vitreous debridement. In patients too ill for eye surgery, a needle aspiration of the vitreous (for stains and cultures) followed by an intravitreal antibiotic injection should be performed.",
"   </p>",
"   <p>",
"    If only the aqueous is involved, then a vitrectomy may not be necessary, but these cases are rare. Even in such cases, intravitreal injection of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    is usually given in addition to injection into the aqueous (intracameral injection). Intravitreal and intracameral injections are discussed below. (See",
"    <a class=\"local\" href=\"#H278655734\">",
"     'Intravitreal antifungal therapy'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H278655727\">",
"     'Intracameral antifungal therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Successful treatment of mold endophthalmitis also requires removal of any foreign material (eg, an intraocular lens placed during cataract surgery, or a foreign body introduced by penetrating eye trauma). Leaving any such foreign material in place may allow persistent infection despite antifungal therapy, and nearly always leads to relapse of infection. Leaving an intraocular lens in place in post-cataract fungal endophthalmitis is a risk factor for poor visual outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2937/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61418791\">",
"    <span class=\"h2\">",
"     Corneal transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Corneal transplantation may be indicated in cases of keratomycosis due to molds in which the infection has extended into the aqueous. This is particularly true in corneas with extensive involvement, corneal melting, impending perforation,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    poor response to treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2937/abstract/6\">",
"     6",
"    </a>",
"    ]. The treatment of Fusarium keratitis is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/42/3753?source=see_link&amp;anchor=H346085004#H346085004\">",
"     \"Treatment and prevention of Fusarium infection\", section on 'Keratitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H278655734\">",
"    <span class=\"h2\">",
"     Intravitreal antifungal therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraocular injection of either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    is necessary for nearly all cases of mold endophthalmitis to ensure the rapid achievement of high levels of an antifungal drug inside the eye. Intravitreal amphotericin B has been used for many years; the usual dose is 5 to 10 mcg in 0.1 mL sterile water. Intravitreal voriconazole has been used successfully in a number of cases, and appears to have less toxicity than amphotericin B [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2937/abstract/1,7,8\">",
"     1,7,8",
"    </a>",
"    ]. No studies have directly compared intravitreal amphotericin B to voriconazole. The usual dose of intravitreal voriconazole is 50 to 100 mcg in 0.1 mL sterile water.",
"   </p>",
"   <p>",
"    Observations regarding the use of intravitreal antifungal therapy (in combination with the other modalities described above) have been reported in the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective study from India of 113 patients with fungal endophthalmitis treated between 1992 and 2005, there were 43 cases of culture-proven mold endophthalmitis (31 caused by Aspergillus spp and 12 due to other molds) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/55/2937/abstract/3\">",
"       3",
"      </a>",
"      ]. The treatment regimen included vitrectomy and 5 mcg of intravitreal",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      in all patients. At three months, of the 43 patients, 36 (84 percent) had a favorable anatomic outcome, and 13 (30 percent) had visual acuity of",
"      <span class=\"nowrap\">",
"       20/400",
"      </span>",
"      or better.",
"     </li>",
"     <li>",
"      In a retrospective review of 41 exogenous fungal endophthalmitis cases seen at an eye institute in Florida between 1990 and 2006, molds accounted for 35 cases (85 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/55/2937/abstract/9\">",
"       9",
"      </a>",
"      ]. Of the 41 cases, 18 were associated with fungal keratitis, 10 occurred after penetrating eye trauma, and 13 occurred after eye surgery. Treatment included intraocular",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      in 88 percent of cases (intravitreally in 30, intracamerally in 8), and 10 patients received intraocular",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      (intravitreally in six, intracamerally in four). Vitrectomy was performed in 61 percent of eyes. Visual outcomes varied significantly between groups. Following treatment, a vision of",
"      <span class=\"nowrap\">",
"       20/400",
"      </span>",
"      or better was achieved in the involved eyes of 22 patients (54 percent), but 21 of these were in the keratitis or postoperative groups. Patients in the post-eye trauma group had poor visual outcomes, and 7 of the 10 involved eyes were enucleated.",
"     </li>",
"     <li>",
"      In other small series and individual case reports of mold endophthalmitis, intravitreal",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      was used with or without other measures, such as vitrectomy or anterior chamber washout, and patients appeared to have improvement [",
"      <a class=\"abstract\" href=\"UTD.htm?2/55/2937/abstract/7,10-13\">",
"       7,10-13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    High doses of intravitreal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    are toxic to the retina, but an intravitreal injection of 5 to 10 mcg (in 0.1 mL sterile water) appears to be safe and may be repeated several days later if evidence of intraocular infection persists on serial examinations. Patients have received cumulative intravitreal doses of 30 mcg amphotericin without apparent retinal toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2937/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based on animal studies and case reports, intravitreal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    also appears to be safe. In in vitro toxicity studies of human retinal pigment epithelium cells and primary human ocular nerve head astrocytes, a concentration of voriconazole of 25",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    vitreous appears to be safe [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2937/abstract/8\">",
"     8",
"    </a>",
"    ]. In a study of rats, a dose of up to 25 mcg per mL vitreous was found to be safe based on electroretinography and histopathology findings [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2937/abstract/15\">",
"     15",
"    </a>",
"    ]. This dose corresponds to an injection of 100 mcg into the adult human vitreous, which has a volume of approximately 4 mL. A dose of 50 to 100 mcg of voriconazole in 0.1 mL sterile water has been used in patients without apparent toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2937/abstract/4,7-12\">",
"     4,7-12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H278655727\">",
"    <span class=\"h2\">",
"     Intracameral antifungal therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In rare cases in which only the aqueous humor is involved, such as in early postcataract mold endophthalmitis or early endophthalmitis due to keratomycosis, an intracameral (into the anterior chamber) injection of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    should be given. Intracameral amphotericin B has been used for many years to treat exogenous fungal endophthalmitis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2937/abstract/16\">",
"     16",
"    </a>",
"    ]. More recently, it has been used to treat refractory cases of keratomycosis, including some with extension into the aqueous [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2937/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Increasingly, intracameral and intravitreal voriconazole have been used in place of amphotericin B. The rationale for intracameral injections is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/16/36102?source=see_link&amp;anchor=H728946907#H728946907\">",
"     \"Treatment of exogenous endophthalmitis due to Candida species\", section on 'Intraocular therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The usual dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    deoxycholate for intracameral injection is 5 mcg in 0.1 mL sterile water. Transient increase in eye pain (lasting up to 12 hours) and anterior chamber inflammation, including hypopyon, have occurred following intracameral amphotericin B injections [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2937/abstract/17,19\">",
"     17,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimal dose of intracameral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    has not been well established, but 50 to 100 mcg in 0.1 mL sterile water is usually used. Intracameral voriconazole has been used without apparent toxicity. In one in vitro study of cultured human ocular cells, a concentration of 250",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    of voriconazole for 30 days did not appear to cause toxicity either to corneal or endothelial trabecular meshwork cells [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2937/abstract/20\">",
"     20",
"    </a>",
"    ]. In another in vitro study, voriconazole concentrations up to 50",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    did not decrease the viability of corneal endothelial cells, but concentrations &ge;100",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    led to a reduction in cell viability [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2937/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several studies have reported effective use of intracameral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    at doses ranging from 12.5 mcg to 100 mcg in 0.1 mL sterile water [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2937/abstract/6,7,9\">",
"     6,7,9",
"    </a>",
"    ]. Intracameral doses of 100 mcg of voriconazole have been used repeatedly in some eyes without any apparent toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2937/abstract/6\">",
"     6",
"    </a>",
"    ], but we prefer a dose of 50 mcg due to the limited experience with intracameral voriconazole and because this dose produces sufficiently high concentrations in the aqueous. A case series from Taiwan evaluated the experience of using intracameral voriconazole to treat 10 eyes with mold endophthalmitis involving only the anterior segment as a consequence of extension of keratomycosis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2937/abstract/6\">",
"     6",
"    </a>",
"    ]. In these patients, 100 mcg of voriconazole was injected intracamerally from one to eight times; seven patients received five or more injections without apparent toxicity. Eyes in which multiple doses were given were injected daily. In four eyes, vision improved at least one Snellen line following treatment, whereas in five eyes, vision did not improve. In all cases, clinical findings suggesting fungal invasion of the anterior chamber resolved after treatment.",
"   </p>",
"   <p>",
"    Intracameral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    has been shown to have a half-life of only 22 minutes in an experimental rabbit model [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2937/abstract/22\">",
"     22",
"    </a>",
"    ], so topical voriconazole 1 percent solution can be used to prolong the drug level in the aqueous. Application of 1 percent voriconazole ophthalmic solution (eyedrops) every 2 hours for 24 hours prior to scheduled eye surgery produced high levels in the aqueous in one study of 13 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2937/abstract/23\">",
"     23",
"    </a>",
"    ]. In cases of exogenous fungal endophthalmitis resulting from fungal keratitis, the keratitis should also be treated with antifungal eyedrops. Topical voriconazole eyedrops (1 percent) are preferred in these cases since topical voriconazole penetrates the cornea and achieves good levels in the aqueous, whereas topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    deoxycholate does not. If voriconazole ophthalmic solution cannot be used (eg, if the fungus is not expected to be susceptible), amphotericin B ophthalmic solution (0.15 percent in sterile water) can be used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H365247006\">",
"    <span class=\"h2\">",
"     Systemic antifungal therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic antifungal therapy is indicated for endogenous mold endophthalmitis, and the choice of systemic therapy should be based on optimal treatment for invasive fungal infection. The treatment of invasive fungal infections is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28970?source=see_link\">",
"     \"Treatment and prevention of invasive aspergillosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/42/3753?source=see_link\">",
"     \"Treatment and prevention of Fusarium infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In exogenous mold endophthalmitis, vitrectomy and intraocular injections of antifungal agents (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    ) alone may suffice, but the addition of systemic voriconazole is almost always indicated unless the fungus is known to be resistant to azoles. Systemic amphotericin B is not usually given in exogenous endophthalmitis because the significant toxicity of this therapy is usually not justified by the minimal benefit, if any. In experimental studies, systemic amphotericin B achieves minimal intraocular levels in uninflamed rabbit eyes, although higher levels are achieved in inflamed rabbit eyes when multiple-dose regimens are used over seven days [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2937/abstract/24\">",
"     24",
"    </a>",
"    ]. Liposomal amphotericin may achieve higher vitreous concentrations than other lipid formulations of amphotericin B or amphotericin B deoxycholate [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2937/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     Voriconazole",
"    </a>",
"    is the treatment of choice for systemic Aspergillus infections; it is also active against Fusarium and these two fungi account for the majority of mold endophthalmitis cases. Voriconazole achieves vitreous levels with oral administration that are nearly 40 percent of plasma levels [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2937/abstract/25\">",
"     25",
"    </a>",
"    ]. In addition to endophthalmitis caused by Aspergillus spp and Fusarium spp, voriconazole has also been used to treat endophthalmitis due to Paecilomyces lilacinus, Scedosporium apiospermum, and Lecythophora mutabilis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2937/abstract/11,26-28\">",
"     11,26-28",
"    </a>",
"    ]. Oral voriconazole, in combination with vitrectomy and intravitreal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    , was used successfully to treat a case of exogenous Fusarium endophthalmitis and a case of Aspergillus endophthalmitis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2937/abstract/29\">",
"     29",
"    </a>",
"    ]. The patient with Aspergillus endophthalmitis also received intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     caspofungin",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    It is important to measure serum concentrations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    approximately one week after initiating systemic therapy to ensure that adequate concentrations have been achieved to allow success and to avoid high levels that have been associated with adverse events. Although debate remains over the optimal target concentration, available data suggest a therapeutic range of greater than 1",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    and less than 5.5",
"    <span class=\"nowrap\">",
"     mg/L.",
"    </span>",
"    In patients with concentrations that are too high or too low, the serum concentration should be rechecked four to five days after adjusting the dose. Once appropriate levels have been achieved, it is not necessary to recheck them unless there is a change in clinical status or concern for toxicity (eg, transaminitis) or drug-drug interactions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link&amp;anchor=H26#H26\">",
"     \"Pharmacology of azoles\", section on 'Serum drug concentration monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The intraocular concentration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    has not been studied in animal models and it may not achieve adequate concentrations in its current formulation, which has highly variable absorption. The best serum concentrations are achieved when posaconazole is given with a fatty food or a drink (eg, Boost), two to four times daily, which is problematic for many patients. However, posaconazole has been used with success as salvage therapy in a few complicated cases of Fusarium keratitis-related endophthalmitis and endophthalmitis that had not responded to therapy with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2937/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. In one patient successfully treated with both topical and oral posaconazole for refractory Fusarium keratitis-related endophthalmitis, the vitreous concentration one week after keratoplasty was approximately 20 percent of the plasma concentration (0.25",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    in vitreous, 1.2",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    in plasma), and the aqueous concentration three months later was 0.9",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    (with plasma level of 1.6",
"    <span class=\"nowrap\">",
"     mcg/mL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2937/abstract/31\">",
"     31",
"    </a>",
"    ] .",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     Fluconazole",
"    </a>",
"    is",
"    <strong>",
"     not",
"    </strong>",
"    recommended because of its poor activity against molds.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     Itraconazole",
"    </a>",
"    is also not usually used due to poor penetration into the vitreous.",
"   </p>",
"   <p>",
"    The echinocandins are active against Aspergillus spp, but not Fusarium spp or other molds. There are few data on the ability of the echinocandins to cross the blood-eye barrier, but adequate concentrations would be unlikely given the large size of these molecules and the high degree of protein binding. In experiments in rabbits of systemically administered",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     caspofungin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/31/44532?source=see_link\">",
"     micafungin",
"    </a>",
"    , these agents were undetectable in the vitreous [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2937/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. However, micafungin produced concentrations in the retina-choroid that were comparable with plasma concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2937/abstract/34\">",
"     34",
"    </a>",
"    ]. An individual case report showed success with caspofungin for a case of postcataract extraction Acremonium endophthalmitis that had failed",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2937/abstract/35\">",
"     35",
"    </a>",
"    ]. Caspofungin plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    was successful in a case of Aspergillus endophthalmitis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2937/abstract/29\">",
"     29",
"    </a>",
"    ], but it is not clear that the addition of caspofungin added to the effectiveness of voriconazole. Echinocandins alone are",
"    <strong>",
"     not",
"    </strong>",
"    recommended for the treatment of mold endophthalmitis given the lack of efficacy data, their limited spectrum of activity against molds, and the concern that vitreous concentrations are low.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H634314720\">",
"    <span class=\"h2\">",
"     Approach to treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to treatment depends on several factors, including whether the infection is exogenous or endogenous, and the infecting agent. With endogenous infections, the treatment depends on whether the patient has a localized ocular infection (versus a systemic infection) at the time of presentation. Most immunocompromised patients have a concurrent systemic fungal infection. In contrast, most patients who have endogenous endophthalmitis as the result of intravenous drug use developed it as a result of transient fungemia and do not have involvement of other sites at the time that the endophthalmitis is detected. Treatment requires a combination of modalities, which may include vitrectomy, aspiration of the aqueous, removal of any foreign body (eg, intraocular lens), corneal transplantation, injection of an antifungal agent into the vitreous",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    aqueous, and systemic antifungal therapy. Specific treatment recommendations are provided below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H66569008\">",
"    <span class=\"h3\">",
"     Exogenous mold endophthalmitis",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H66568942\">",
"    <span class=\"h4\">",
"     Anterior chamber involvement only",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with endophthalmitis involving only the anterior chamber, such as from extension of mold keratomycosis, we suggest the following treatment approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Aspirate the aqueous for stains and cultures. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13849?source=see_link&amp;anchor=H27883777#H27883777\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of fungal endophthalmitis\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Surgically remove any foreign body, such as an intraocular lens (eg, placed during prior cataract surgery).",
"     </li>",
"     <li>",
"      Inject either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      (50 mcg in 0.1 mL sterile water) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      (5 mcg in 0.1 mL sterile water) into the aqueous.",
"     </li>",
"     <li>",
"      Corneal transplantation may be indicated in cases of keratomycosis due to molds in which the infection has extended into the aqueous. The management of Fusarium keratitis is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/42/3753?source=see_link&amp;anchor=H346085004#H346085004\">",
"       \"Treatment and prevention of Fusarium infection\", section on 'Keratitis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Administer topical antifungal drops (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      1 percent or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      0.15 percent in sterile water) hourly. Topical voriconazole is preferred for susceptible fungi since it penetrates the cornea well and achieves good concentrations in the aqueous humor.",
"     </li>",
"     <li>",
"      Administer systemic",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      (6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV every 12 hours for two doses, then 4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV every 12 hours for patients with severe disease). Oral therapy, using 200 mg twice daily on an empty stomach can be used following an initial response to the IV formulation. In less severe cases, oral voriconazole can be used as initial therapy; the oral loading dose is 400 mg twice daily for two doses, followed by 200 mg twice daily. Some patients may require higher doses than 200 mg twice daily to achieve adequate serum concentrations (eg, obese patients, young patients). As noted above, it is important to measure serum concentrations of voriconazole approximately one week after initiating systemic therapy to ensure that adequate concentrations have been achieved to allow success and to avoid high levels that have been associated with adverse events. (See",
"      <a class=\"local\" href=\"#H365247006\">",
"       'Systemic antifungal therapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link&amp;anchor=H20#H20\">",
"       \"Pharmacology of azoles\", section on 'Dosing'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link&amp;anchor=H26#H26\">",
"       \"Pharmacology of azoles\", section on 'Serum drug concentration monitoring'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Even if there is no apparent vitreous involvement, consider injecting",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      (100 mcg in 0.1 mL sterile water) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      deoxycholate (5 to 10 mcg in 0.1 mL sterile water) into the vitreous since there may be occult vitreous infection.",
"     </li>",
"     <li>",
"      Repeat injection of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      into the aqueous",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      vitreous after several days if no improvement has occurred. (See",
"      <a class=\"local\" href=\"#H278655727\">",
"       'Intracameral antifungal therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H66568950\">",
"       'Vitreous involvement'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H66568950\">",
"    <span class=\"h4\">",
"     Vitreous involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with exogenous endophthalmitis involving the vitreous, we suggest the following treatment approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Perform a vitrectomy to decrease the fungal burden and to obtain a sample for stains and cultures (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13849?source=see_link&amp;anchor=H27883777#H27883777\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of fungal endophthalmitis\", section on 'Diagnosis'",
"      </a>",
"      ). In the rare case in which the retina specialist feels that he or she cannot safely perform a vitrectomy or in patients too ill for eye surgery, a vitreous aspirate should be obtained for stains and cultures, although the diagnostic yield is lower than with vitrectomy. Surgically remove any foreign body, such as an intraocular lens (eg, placed during prior cataract surgery).",
"     </li>",
"     <li>",
"      Administer an intravitreal injection of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      deoxycholate (5 to 10 mcg in 0.1 mL sterile water) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      (100 mcg in 0.1 mL sterile water). A repeat injection may be indicated after several days if there has been no response to therapy. We favor the first injection to be amphotericin B if the identity of fungus is unknown, but we prefer voriconazole for subsequent injections if the fungus is susceptible. More than one repeat intravitreal injection may be given.",
"     </li>",
"     <li>",
"      If there is involvement of the aqueous, administer an intracameral injection of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      (50 mcg in 0.1 mL sterile water) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      deoxycholate (5 mcg in 0.1 mL sterile water).",
"     </li>",
"     <li>",
"      Administer systemic",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      (6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV every 12 hours for two doses, then 4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV every 12 hours). The IV formulation is recommended for at least the initial few days for patients who have an acute presentation. Oral therapy at a dose of 200 mg twice daily taken on an empty stomach can be used following an initial response to the IV formulation. Some patients may require higher doses than 200 mg twice daily to achieve adequate serum concentrations (eg, obese patients, young patients). As noted above, it is important to measure serum concentrations of voriconazole approximately one week after initiating systemic therapy to ensure that adequate concentrations have been achieved to allow success and to avoid high levels that have been associated with adverse events (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28970?source=see_link&amp;anchor=H7#H7\">",
"       \"Treatment and prevention of invasive aspergillosis\", section on 'Voriconazole'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link&amp;anchor=H23#H23\">",
"       \"Pharmacology of azoles\", section on 'Voriconazole'",
"      </a>",
"      ). If the fungus is resistant to voriconazole, or has recurred despite maximal therapy (eg, repeated intravitreal injections or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      or voriconazole, vitrectomy, removal of all foreign material such as an intraocular lens, removal of an infected cornea if present), then systemic liposomal amphotericin could be used, but these cases are rare.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H79284393\">",
"    <span class=\"h3\">",
"     Endogenous endophthalmitis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Perform a vitrectomy to decrease the fungal burden and to obtain a sample for stains and cultures (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13849?source=see_link&amp;anchor=H27883777#H27883777\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of fungal endophthalmitis\", section on 'Diagnosis'",
"      </a>",
"      ). In the rare case in which the retina specialist feels that he or she cannot safely perform a vitrectomy, or in patients too ill for eye surgery, a vitreous aspirate should be obtained for stains and cultures, although the diagnostic yield is lower than with vitrectomy.",
"     </li>",
"     <li>",
"      Surgically remove any foreign material (eg, intraocular lens).",
"     </li>",
"     <li>",
"      Administer intravitreal",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      deoxycholate (5 to 10 mcg in 0.1 mL) or intravitreal",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      (100 mcg in 0.1 mL). Repeat the intravitreal injection of voriconazole or amphotericin B after several days if no improvement has occurred.",
"     </li>",
"     <li>",
"      We recommend that the first injection be",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      if the identity of fungus is unknown, but we recommend",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      for subsequent injections if the fungus is one likely to be susceptible. Administer systemic antifungal therapy, optimized to the most likely fungal pathogen involved. This may be either a systemic amphotericin B formulation or voriconazole. The usual dosing of these agents is:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"       Liposomal amphotericin B",
"      </a>",
"      &ndash; 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV once daily; we favor this formulation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      because it achieves higher concentrations in the central nervous system compared with other lipid formulations or amphotericin B deoxycholate; the blood-eye barrier is similar to the blood-brain barrier. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/40/39559?source=see_link&amp;anchor=H10#H10\">",
"       \"Candida infections of the central nervous system\", section on 'Antifungal therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       Voriconazole",
"      </a>",
"      &ndash; 6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV every 12 hours for two doses, then 4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV every 12 hours. The IV formulation is recommended for at least the initial few days. Oral therapy at a dose of 200 mg twice daily on an empty stomach can be used following an initial response to the IV formulation. Higher doses may be required in obese patients. As noted above, it is important to measure serum concentrations of voriconazole approximately one week after initiating systemic therapy to ensure that adequate concentrations have been achieved to allow success and to avoid high levels that have been associated with adverse events. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28970?source=see_link&amp;anchor=H7#H7\">",
"       \"Treatment and prevention of invasive aspergillosis\", section on 'Voriconazole'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link&amp;anchor=H23#H23\">",
"       \"Pharmacology of azoles\", section on 'Voriconazole'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The treatment of invasive aspergillosis and fusariosis is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28970?source=see_link\">",
"     \"Treatment and prevention of invasive aspergillosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/42/3753?source=see_link\">",
"     \"Treatment and prevention of Fusarium infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H165207918\">",
"    <span class=\"h3\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The duration of systemic antifungal therapy for mold endophthalmitis depends upon the improvement of lesions as determined by serial ophthalmic examinations, but also whether the infection was exogenous or endogenous. If exogenous, therapy is usually continued for at least one month (and sometimes several months) after resolution of any signs of active intraocular infection. For endogenous endophthalmitis, the duration of therapy is determined by the systemic fungal infection being treated; treatment usually extends for several months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H234846856\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Even with treatment, at least two-thirds of patients with mold endophthalmitis lose useful vision [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2937/abstract/16,36,37\">",
"     16,36,37",
"    </a>",
"    ]. In a comprehensive review of endogenous Aspergillus endophthalmitis, only seven of 84 patients (8 percent) regained useful vision [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2937/abstract/4\">",
"     4",
"    </a>",
"    ]. Six of the seven had been treated with intravenous and intravitreal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    and vitrectomy. The prognosis may be improving with the availability of newer antifungal agents, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H346086707\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Endophthalmitis due to molds is rarely diagnosed in temperate climates, but it is common in tropical regions. Fusarium and Aspergillus spp account for most cases of mold endophthalmitis. Mold endophthalmitis often results in loss of vision. (See",
"      <a class=\"local\" href=\"#H634314692\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A sample of vitreous",
"      <span class=\"nowrap\">",
"       (and/or",
"      </span>",
"      aqueous, if it is involved) should be obtained for stains and cultures prior to antifungal treatment. (See",
"      <a class=\"local\" href=\"#H634314720\">",
"       'Approach to treatment'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13849?source=see_link&amp;anchor=H27883777#H27883777\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of fungal endophthalmitis\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The approach to treatment depends on several factors, including whether the infection is exogenous or endogenous. (See",
"      <a class=\"local\" href=\"#H634314720\">",
"       'Approach to treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with mold endophthalmitis require aggressive treatment with a combination of modalities that includes surgery to remove any foreign bodies, vitrectomy in most cases, and intraocular and systemic antifungal therapy. We use the following approach:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      All foreign bodies should be surgically removed. (See",
"      <a class=\"local\" href=\"#H634314720\">",
"       'Approach to treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       For patients with exogenous mold endophthalmitis involving the anterior chamber only",
"      </strong>",
"      , we recommend intracameral (into the aqueous) injection of either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      (50 mcg in 0.1 mL sterile water) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      (5 mcg in 0.1 mL sterile water) (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). In such patients, we also recommend topical antifungal drops (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). We prefer voriconazole (1 percent topical solution) rather than amphotericin B drops. Intravitreal voriconazole injection should also be considered even if there is no apparent vitreous involvement, since this involvement may be occult. (See",
"      <a class=\"local\" href=\"#H66568942\">",
"       'Anterior chamber involvement only'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When exogenous mold endophthalmitis involving the aqueous arises from extension of keratomycosis, a corneal transplant may also be indicated to reduce the fungal burden and control the infection. The management of Fusarium keratitis is discussed in detail separately. (See",
"      <a class=\"local\" href=\"#H66568942\">",
"       'Anterior chamber involvement only'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/42/3753?source=see_link&amp;anchor=H346085004#H346085004\">",
"       \"Treatment and prevention of Fusarium infection\", section on 'Keratitis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       For patients with exogenous or endogenous mold endophthalmitis involving the vitreous,",
"      </strong>",
"      we recommend a vitrectomy to debride the vitreous in nearly all cases (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). A sample of vitreous should be sent for stains and cultures. An intravitreal injection of either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      (voriconazole if the fungus is susceptible) should be administered at the end of the case. If the ophthalmologist considers a vitrectomy too risky, or if the patient is too ill for eye surgery, a needle aspiration of the vitreous (for stains and cultures) followed by injection of either amphotericin B or voriconazole, should be performed. The usual dose of intravitreal amphotericin B deoxycholate is 5 to 10 mcg in 0.1 mL sterile water, and the usual dose of intravitreal voriconazole is 100 mcg in 0.1 mL sterile water. (See",
"      <a class=\"local\" href=\"#H66568950\">",
"       'Vitreous involvement'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      If the eye has not improved, we favor a repeat intravitreal injection of either voriconazole (for susceptible fungi) or amphotericin B after several days. Intravitreal voriconazole (100 mcg in 0.1 mL of sterile water) is preferred over intravitreal amphotericin (5 to 10 mcg in 0.1 mL sterile water) for fungi susceptible to voriconazole. Intravitreal injections may be repeated more than once for eyes that fail to improve despite maximal therapy (ie, vitrectomy, removal of foreign material, intravitreal and systemic antifungal therapy). (See",
"      <a class=\"local\" href=\"#H66568950\">",
"       'Vitreous involvement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       For all patients with exogenous mold endophthalmitis due to",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      <strong>",
"       -susceptible fungi",
"      </strong>",
"      , we recommend systemic voriconazole (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H66569008\">",
"       'Exogenous mold endophthalmitis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H79284393\">",
"       'Endogenous endophthalmitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Patients with endogenous mold endophthalmitis",
"      </strong>",
"      require systemic antifungal therapy with either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"       liposomal amphotericin B",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      , depending on the susceptibility of the mold. (See",
"      <a class=\"local\" href=\"#H79284393\">",
"       'Endogenous endophthalmitis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The treatment of endophthalmitis due to Candida spp is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/12/39112?source=see_link\">",
"       \"Treatment of endogenous endophthalmitis due to Candida species\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/16/36102?source=see_link\">",
"       \"Treatment of exogenous endophthalmitis due to Candida species\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2937/abstract/1\">",
"      Riddell J 4th, Comer GM, Kauffman CA. Treatment of endogenous fungal endophthalmitis: focus on new antifungal agents. Clin Infect Dis 2011; 52:648.",
"     </a>",
"    </li>",
"    <li>",
"     Durand ML. Endophthalmitis. In: Principles and Practice of Infectious Diseases, 7th edition, Mandell GL, Bennett JE, Dolin R.  (Eds), Churchill Livingstone Elsevier, Philadelphia 2010. Vol 1, p.1553.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2937/abstract/3\">",
"      Chakrabarti A, Shivaprakash MR, Singh R, et al. Fungal endophthalmitis: fourteen years' experience from a center in India. Retina 2008; 28:1400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2937/abstract/4\">",
"      Riddell Iv J, McNeil SA, Johnson TM, et al. Endogenous Aspergillus endophthalmitis: report of 3 cases and review of the literature. Medicine (Baltimore) 2002; 81:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2937/abstract/5\">",
"      G&uuml;ngel H, Eren MH, P��narc�� EY, et al. An outbreak of Fusarium solani endophthalmitis after cataract surgery in an eye training and research hospital in Istanbul. Mycoses 2011; 54:e767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2937/abstract/6\">",
"      Shen YC, Wang CY, Tsai HY, Lee HN. Intracameral voriconazole injection in the treatment of fungal endophthalmitis resulting from keratitis. Am J Ophthalmol 2010; 149:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2937/abstract/7\">",
"      Lin RC, Sanduja N, Hariprasad SM. Successful treatment of postoperative fungal endophthalmitis using intravitreal and intracameral voriconazole. J Ocul Pharmacol Ther 2008; 24:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2937/abstract/8\">",
"      Kernt M, Neubauer AS, De Kaspar HM, Kampik A. Intravitreal voriconazole: in vitro safety-profile for fungal endophthalmitis. Retina 2009; 29:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2937/abstract/9\">",
"      Wykoff CC, Flynn HW Jr, Miller D, et al. Exogenous fungal endophthalmitis: microbiology and clinical outcomes. Ophthalmology 2008; 115:1501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2937/abstract/10\">",
"      Sen P, Gopal L, Sen PR. Intravitreal voriconazole for drug-resistant fungal endophthalmitis: case series. Retina 2006; 26:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2937/abstract/11\">",
"      Kramer M, Kramer MR, Blau H, et al. Intravitreal voriconazole for the treatment of endogenous Aspergillus endophthalmitis. Ophthalmology 2006; 113:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2937/abstract/12\">",
"      Vila Arteaga J, Suriano MM, Stirbu O. Intravitreal voriconazole for the treatment of Aspergillus chorioretinitis. Int Ophthalmol 2011; 31:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2937/abstract/13\">",
"      Belenitsky MP, Liu C, Tsui I. Scedosporium apiospermum endopthalmitis treated early with intravitreous voriconazole results in recovery of vision. J Ophthalmic Inflamm Infect 2012; 2:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2937/abstract/14\">",
"      Tabbara KF, al Jabarti AL. Hospital construction-associated outbreak of ocular aspergillosis after cataract surgery. Ophthalmology 1998; 105:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2937/abstract/15\">",
"      Gao H, Pennesi ME, Shah K, et al. Intravitreal voriconazole: an electroretinographic and histopathologic study. Arch Ophthalmol 2004; 122:1687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2937/abstract/16\">",
"      Pflugfelder SC, Flynn HW Jr, Zwickey TA, et al. Exogenous fungal endophthalmitis. Ophthalmology 1988; 95:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2937/abstract/17\">",
"      Yilmaz S, Ture M, Maden A. Efficacy of intracameral amphotericin B injection in the management of refractory keratomycosis and endophthalmitis. Cornea 2007; 26:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2937/abstract/18\">",
"      Yoon KC, Jeong IY, Im SK, et al. Therapeutic effect of intracameral amphotericin B injection in the treatment of fungal keratitis. Cornea 2007; 26:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2937/abstract/19\">",
"      Kuriakose T, Kothari M, Paul P, et al. Intracameral amphotericin B injection in the management of deep keratomycosis. Cornea 2002; 21:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2937/abstract/20\">",
"      Kernt M, Kampik A. Intracameral voriconazole: in vitro safety for human ocular cells. Toxicology 2009; 258:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2937/abstract/21\">",
"      Han SB, Shin YJ, Hyon JY, Wee WR. Cytotoxicity of voriconazole on cultured human corneal endothelial cells. Antimicrob Agents Chemother 2011; 55:4519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2937/abstract/22\">",
"      Shen YC, Wang MY, Wang CY, et al. Pharmacokinetics of intracameral voriconazole injection. Antimicrob Agents Chemother 2009; 53:2156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2937/abstract/23\">",
"      Vemulakonda GA, Hariprasad SM, Mieler WF, et al. Aqueous and vitreous concentrations following topical administration of 1% voriconazole in humans. Arch Ophthalmol 2008; 126:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2937/abstract/24\">",
"      Goldblum D, Rohrer K, Frueh BE, et al. Ocular distribution of intravenously administered lipid formulations of amphotericin B in a rabbit model. Antimicrob Agents Chemother 2002; 46:3719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2937/abstract/25\">",
"      Hariprasad SM, Mieler WF, Holz ER, et al. Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans. Arch Ophthalmol 2004; 122:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2937/abstract/26\">",
"      Garbino J, Ondrusova A, Baglivo E, et al. Successful treatment of Paecilomyces lilacinus endophthalmitis with voriconazole. Scand J Infect Dis 2002; 34:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2937/abstract/27\">",
"      Figueroa MS, Fortun J, Clement A, De Ar&eacute;valo BF. Endogenous endophthalmitis caused by Scedosporium apiospermum treated with voriconazole. Retina 2004; 24:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2937/abstract/28\">",
"      Scott IU, Cruz-Villegas V, Flynn HW Jr, Miller D. Delayed-onset, bleb-associated endophthalmitis caused by Lecythophora mutabilis. Am J Ophthalmol 2004; 137:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2937/abstract/29\">",
"      Durand ML, Kim IK, D'Amico DJ, et al. Successful treatment of Fusarium endophthalmitis with voriconazole and Aspergillus endophthalmitis with voriconazole plus caspofungin. Am J Ophthalmol 2005; 140:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2937/abstract/30\">",
"      Tu EY, McCartney DL, Beatty RF, et al. Successful treatment of resistant ocular fusariosis with posaconazole (SCH-56592). Am J Ophthalmol 2007; 143:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2937/abstract/31\">",
"      Sponsel WE, Graybill JR, Nevarez HL, Dang D. Ocular and systemic posaconazole(SCH-56592) treatment of invasive Fusarium solani keratitis and endophthalmitis. Br J Ophthalmol 2002; 86:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2937/abstract/32\">",
"      Spriet I, Delaere L, Lagrou K, et al. Intraocular penetration of voriconazole and caspofungin in a patient with fungal endophthalmitis. J Antimicrob Chemother 2009; 64:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2937/abstract/33\">",
"      Goldblum D, Fausch K, Frueh BE, et al. Ocular penetration of caspofungin in a rabbit uveitis model. Graefes Arch Clin Exp Ophthalmol 2007; 245:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2937/abstract/34\">",
"      Suzuki T, Uno T, Chen G, Ohashi Y. Ocular distribution of intravenously administered micafungin in rabbits. J Infect Chemother 2008; 14:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2937/abstract/35\">",
"      Cornely OA, Schmitz K, Aisenbrey S. The first echinocandin: caspofungin. Mycoses 2002; 45 Suppl 3:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2937/abstract/36\">",
"      Essman TF, Flynn HW Jr, Smiddy WE, et al. Treatment outcomes in a 10-year study of endogenous fungal endophthalmitis. Ophthalmic Surg Lasers 1997; 28:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2937/abstract/37\">",
"      Dursun D, Fernandez V, Miller D, Alfonso EC. Advanced fusarium keratitis progressing to endophthalmitis. Cornea 2003; 22:300.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16205 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-183.166.191.243-B4DFEB0FC9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_55_2937=[""].join("\n");
var outline_f2_55_2937=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H346086707\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H634314692\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H198244885\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H634314713\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H365246849\">",
"      Vitrectomy and removal of foreign bodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H61418791\">",
"      Corneal transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H278655734\">",
"      Intravitreal antifungal therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H278655727\">",
"      Intracameral antifungal therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H365247006\">",
"      Systemic antifungal therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H634314720\">",
"      Approach to treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H66569008\">",
"      - Exogenous mold endophthalmitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H66568942\">",
"      Anterior chamber involvement only",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H66568950\">",
"      Vitreous involvement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H79284393\">",
"      - Endogenous endophthalmitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H165207918\">",
"      - Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H234846856\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H346086707\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/16205\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/16205|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/35/42549\" title=\"figure 1\">",
"      Eye anatomy in cross section",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/11/30899\" title=\"figure 2\">",
"      Vitreous aspirate vitrectomy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/18/24873?source=related_link\">",
"      Bacterial endophthalmitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/40/39559?source=related_link\">",
"      Candida infections of the central nervous system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13849?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of fungal endophthalmitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=related_link\">",
"      Pharmacology of azoles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/42/3753?source=related_link\">",
"      Treatment and prevention of Fusarium infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28970?source=related_link\">",
"      Treatment and prevention of invasive aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/12/39112?source=related_link\">",
"      Treatment of endogenous endophthalmitis due to Candida species",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/16/36102?source=related_link\">",
"      Treatment of exogenous endophthalmitis due to Candida species",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_55_2938="Epidemiology, pathogenesis, and etiology of pneumonia in children";
var content_f2_55_2938=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology, pathogenesis, and etiology of pneumonia in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/55/2938/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/55/2938/contributors\">",
"     William J Barson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/55/2938/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/55/2938/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/55/2938/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/55/2938/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/55/2938/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 9, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Childhood pneumonia is an important cause of morbidity in the developed world, and morbidity and mortality in the developing world. The epidemiology, microbiology, and pathogenesis of pneumonia in children will be reviewed here. The clinical features, diagnosis, and treatment of pneumonia in children are discussed separately, as is pneumonia in neonates (&lt;28 days of age). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38970?source=see_link\">",
"     \"Clinical features and diagnosis of community-acquired pneumonia in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/46/27369?source=see_link\">",
"     \"Outpatient treatment of community-acquired pneumonia in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/48/25354?source=see_link\">",
"     \"Inpatient treatment of pneumonia in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/0/21512?source=see_link\">",
"     \"Neonatal pneumonia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The terms pneumonia and pneumonitis strictly represent any inflammatory condition involving the lungs, which include the visceral pleura, connective tissue, airways, alveoli, and vascular structures. Lower respiratory tract infection (LRTI) is frequently used interchangeably to include bronchitis, bronchiolitis, and pneumonia, or any combination of the three. For the purposes of this review, pneumonia will be defined as a condition typically associated with fever, respiratory symptoms, and evidence of parenchymal involvement, either by physical examination or the presence of infiltrates on chest radiography. Bronchiolitis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/44/16074?source=see_link&amp;anchor=H7#H7\">",
"     \"Bronchiolitis in infants and children: Clinical features and diagnosis\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The World Health Organization (WHO) estimates there are 156 million cases of pneumonia each year in children younger than five years, with as many as 20 million cases severe enough to require hospital admission [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2938/abstract/1\">",
"     1",
"    </a>",
"    ]. In the developed world, the annual incidence of pneumonia is estimated to be 33 per 10,000 in children younger than five years and 14.5 per 10,000 in children 0 to 16 years [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2938/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approximately one-half of children younger than five years of age with community-acquired pneumonia (CAP) require hospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2938/abstract/3\">",
"     3",
"    </a>",
"    ]. Hospitalization rates for pneumonia (all causes) among children younger than two years in the United States decreased after introduction of the pneumococcal conjugate vaccine to the routine childhood immunization schedule in 2000 (from 12 to 14 per 1000 population to 8 to 10 per 1000 population) (",
"    <a class=\"graphic graphic_figure graphicRef52194 \" href=\"UTD.htm?26/33/27166\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2938/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mortality rate in developed countries is low (&lt;1 per 1000 per year) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2938/abstract/5\">",
"     5",
"    </a>",
"    ]. In developing countries, respiratory tract infections are not only more prevalent but more severe, accounting for more than 2 million deaths annually; pneumonia is the number one killer of children in these societies [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2938/abstract/1,6\">",
"     1,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Seasonality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although both viral and bacterial pneumonia occur throughout the year, they are more prevalent during the colder months, presumably because direct transmission of infected droplets is enhanced by indoor crowding. For reasons that are unknown, different viruses cause peaks of infection at different times during the respiratory virus season and these peaks seldom occur simultaneously [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2938/abstract/7\">",
"     7",
"    </a>",
"    ]. In tropical regions, peaks of infection follow no common pattern and can occur during either the wet or dry seasons.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most studies have shown that pediatric lower respiratory tract infection (LRTI), including pneumonia, are more frequent in boys, with a male-female ratio of 1.25:1 to 2:1 [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2938/abstract/8\">",
"     8",
"    </a>",
"    ]. Lower socioeconomic groups have a higher prevalence of LRTIs, which correlates best with family size, a reflection of environmental crowding. School-age children often introduce respiratory viral agents into households, resulting in secondary infections in their parents and siblings [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2938/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Underlying cardiopulmonary disorders and other medical conditions predispose to pneumonia and contribute to increasing severity. These include [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2938/abstract/5,9\">",
"     5,9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Congenital heart disease",
"     </li>",
"     <li>",
"      Bronchopulmonary dysplasia",
"     </li>",
"     <li>",
"      Cystic fibrosis",
"     </li>",
"     <li>",
"      Asthma",
"     </li>",
"     <li>",
"      Sickle cell disease",
"     </li>",
"     <li>",
"      Neuromuscular disorders, especially those associated with a depressed consciousness",
"     </li>",
"     <li>",
"      Some gastrointestinal disorders (eg, gastroesophageal reflux, tracheoesophageal fistula)",
"     </li>",
"     <li>",
"      Congenital and acquired immunodeficiency disorders",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cigarette smoke compromises natural pulmonary defense mechanisms by disrupting both mucociliary function and macrophage activity [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2938/abstract/10\">",
"     10",
"    </a>",
"    ]. Exposure to cigarette smoke, especially if the mother smokes, increases the risk for pneumonia in infants younger than one year of age. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/4/5194?source=see_link\">",
"     \"Secondhand smoke exposure: Effects in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of cigarettes, alcohol, and other substances of abuse in adolescents may increase the risk of pneumonia by increasing the risk of aspiration through impairment of the cough and epiglottic reflexes. In addition, the use of alcohol has been associated with increased colonization of the oropharynx with aerobic gram-negative bacilli [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2938/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Effect of vaccines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunization with the",
"    <em>",
"     Haemophilus influenzae",
"    </em>",
"    type b (Hib) and pneumococcal conjugate vaccines protects children from invasive disease caused by these organisms. Hib was once a common cause of pneumonia in young children in the United States. However, it has been virtually eliminated as a result of routine immunization with Hib conjugate vaccines. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42489?source=see_link&amp;anchor=H7#H7\">",
"     \"Prevention of Haemophilus influenzae infection\", section on 'Efficacy/effectiveness'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The universal immunization of infants in the United States with the 7-valent pneumococcal conjugate vaccine has effectively decreased the incidence of pneumonia requiring hospitalization and other invasive",
"    <em>",
"     Streptococcus pneumoniae",
"    </em>",
"    infections in children younger than two years (",
"    <a class=\"graphic graphic_figure graphicRef52194 \" href=\"UTD.htm?26/33/27166\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2938/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Rates of ambulatory visits for pneumonia in children younger than two years also declined after the introduction of pneumococcal conjugate vaccine [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2938/abstract/14\">",
"     14",
"    </a>",
"    ], but the rates for children aged 1 to 18 years remained stable [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2938/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7402?source=see_link&amp;anchor=H10#H10\">",
"     \"Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children\", section on 'Pneumonia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is anticipated that the 13-valent pneumococcal conjugate vaccine that replaced the 7-valent pneumococcal conjugate vaccine in 2010 and affords additional coverage against serotypes 1, 3, 5, 6A, 7F, and 19A will further decrease the incidence of pneumonia requiring hospitalization because these serotypes currently are responsible for the majority of pneumococcal pneumonia cases among children worldwide [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2938/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7402?source=see_link&amp;anchor=H4#H4\">",
"     \"Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children\", section on '13-valent vaccine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pneumococcal vaccination also protects against viral pneumonia. This was shown in a double-blind, randomized, placebo-controlled trial in which full immunization with a nine-valent pneumococcal conjugate vaccine was associated with a 31 percent reduction (95% CI 15-43) in the incidence of pneumonia associated with any of seven respiratory viruses (influenza, parainfluenza, respiratory syncytial virus (RSV), adenovirus) in hospitalized children [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2938/abstract/18\">",
"     18",
"    </a>",
"    ]. This observation suggests that the pneumonias associated with these viruses in hospitalized children are often because of concurrent pneumococcal infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pneumonia occurs because of an impairment of host defenses, invasion by a virulent organism,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    invasion by an overwhelming inoculum.",
"   </p>",
"   <p>",
"    In the typical scenario, pneumonia follows an upper respiratory tract illness that permits invasion of the lower respiratory tract by bacteria, viruses, or other pathogens that trigger the immune response and produce inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2938/abstract/3,19\">",
"     3,19",
"    </a>",
"    ]. The lower respiratory tract air spaces fill with white blood cells (WBC), fluid, and cellular debris. This process reduces lung compliance, increases resistance, obstructs smaller airways, and may result in collapse of distal air spaces, air trapping, and altered ventilation-perfusion relationships [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2938/abstract/3\">",
"     3",
"    </a>",
"    ]. Severe infection is associated with necrosis of bronchial or bronchiolar epithelium [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2938/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Acquisition",
"    </span>",
"    &nbsp;&mdash;&nbsp;The agents that cause lower respiratory tract infection (LRTI) are most often transmitted by droplet spread resulting from close contact with a source case. Contact with contaminated fomites also may be important in the acquisition of viral agents, especially respiratory syncytial virus (RSV).",
"   </p>",
"   <p>",
"    Most typical bacterial pneumonias are the result of initial colonization of the nasopharynx followed by aspiration or inhalation of organisms. Invasive disease most commonly occurs upon acquisition of a new serotype of the organism with which the patient has not had previous experience, typically after an incubation period of one to three days. Occasionally, a primary bacteremia may precede the pneumonia. Atypical bacterial pathogens attach to respiratory epithelial membranes through which they enter cells for replication.",
"   </p>",
"   <p>",
"    The viral agents that cause pneumonia proliferate and spread by contiguity to involve lower and more distal portions of the respiratory tract.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Normal host defense",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pulmonary host defense system is complex and includes anatomic and mechanical barriers, humoral immunity, phagocytic activity, and cell-mediated immunity [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2938/abstract/8,21,22\">",
"     8,21,22",
"    </a>",
"    ], as discussed below, with a focus on bacterial infection. The host response to respiratory viral infection is beyond the scope of this review; more information can be obtained from reference [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2938/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anatomic and mechanical barriers &ndash; Anatomic and mechanical barriers in the upper airway comprise an important part of the host defense. Particles greater than 10 microns are efficiently filtered by the hairs in the anterior nares or impact onto mucosal surfaces. The nasal mucosa contains ciliated epithelium and mucus-producing cells. The cilia beat synchronously, clearing the entrapped organisms through the nasopharynx via expulsion or swallowing. In the oropharynx, salivary flow, sloughing of epithelial cells, local production of complement and IgA, and bacterial interference from the resident flora serve as important factors in local host defense.",
"      <br/>",
"      <br/>",
"      An intact epiglottic reflex helps to prevent aspiration of infected secretions, and the cough reflex helps to expel materials that may be aspirated. The sharp angles at which the central airways branch cause 5 to 10 micron particles to impact on mucosal surfaces, where they are entrapped in endobronchial mucus. Once entrapped, the ciliary system moves the particles upward out of the airways into the throat, where they are normally swallowed.",
"     </li>",
"     <li>",
"      Humoral immunity &ndash; Secretory IgA is the major immunoglobulin produced in the upper airways and accounts for 10 percent of the total protein concentration of nasal secretions. Although it is not a very good opsonizing agent, it does possess antibacterial and antiviral activity. IgG and IgM enter the airways and alveolar spaces predominantly via transudation from the blood and act to opsonize bacteria, activate complement, and neutralize toxin. Immunoglobulins, surfactant, fibronectin, and complement act as effective opsonins to help eliminate microorganisms (0.5 to 1 micron particles) that reach the terminal airways and alveoli. Free fatty acids, lysozyme, and iron-binding proteins also are present and may be microbicidal.",
"     </li>",
"     <li>",
"      Phagocytic cells &ndash; There are two populations of phagocytic cells in the lung: polymorphonuclear leukocytes (PMNs) from the blood and macrophages. There are several distinct populations of macrophages, which vary in their location and function:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The alveolar macrophage is located in the alveolar fluid and is the first phagocyte encountered by inert particles and potential pathogens entering the lung. If this cell is overwhelmed, it has the capacity to become a mediator of inflammation and produce cytokines that recruit neutrophils.",
"     </li>",
"     <li>",
"      Interstitial macrophages are located in the lung connective tissue and serve both as phagocytic cells and antigen-processing cells.",
"     </li>",
"     <li>",
"      The intravascular macrophage is located in capillary endothelial cells and phagocytizes and removes foreign material entering the lungs via the bloodstream.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cell-mediated immunity &ndash; Cell-mediated immunity is especially important against certain pathogens, including viruses and intracellular microorganisms that can survive within pulmonary macrophages. Although relatively few in number (5 to 10 percent of the total lung parenchyma cell population), lymphocytes play three critical roles: the production of antibody, cytotoxic activity, and the production of cytokines.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Patterns of pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are five patterns of bacterial pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2938/abstract/19\">",
"     19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lobar pneumonia &ndash; involvement of a single lobe or segment of a lobe; this is the classic pattern of",
"      <em>",
"       S. pneumoniae",
"      </em>",
"      pneumonia",
"     </li>",
"     <li>",
"      Bronchopneumonia &ndash; primary involvement of airways and surrounding interstitium; this pattern is sometimes seen in",
"      <em>",
"       Streptococcus pyogenes",
"      </em>",
"      and",
"      <em>",
"       Staphylococcus aureus",
"      </em>",
"      pneumonia",
"     </li>",
"     <li>",
"      Necrotizing pneumonia (associated with aspiration pneumonia and pneumonia resulting from",
"      <em>",
"       S. pneumoniae",
"      </em>",
"      ,",
"      <em>",
"       S. pyogenes",
"      </em>",
"      , and",
"      <em>",
"       S. aureus",
"      </em>",
"      ) (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef86362 \" href=\"UTD.htm?19/30/19941\">",
"       image 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Caseating granuloma (as in tuberculosis pneumonia)",
"     </li>",
"     <li>",
"      Interstitial and peribronchiolar with secondary parenchymal infiltration &ndash; this pattern typically occurs when a severe viral pneumonia is complicated by bacterial pneumonia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are two patterns of viral pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2938/abstract/19\">",
"     19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Interstitial pneumonitis (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef82288 \" href=\"UTD.htm?31/14/31973\">",
"       image 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Parenchymal infection with viral inclusions",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Examination findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The examination findings vary depending on the site of infection as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2938/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inspiratory crackles, also called rales and crepitations [",
"      <a class=\"abstract\" href=\"UTD.htm?2/55/2938/abstract/24\">",
"       24",
"      </a>",
"      ], are more common in lobar pneumonia and",
"      <span class=\"nowrap\">",
"       bronchiolitis/pneumonia",
"      </span>",
"     </li>",
"     <li>",
"      Decreased breath sounds may be noted in areas of consolidation",
"     </li>",
"     <li>",
"      Coarse, low-pitched continuous breath sounds (rhonchi) are more common in bronchopneumonia",
"     </li>",
"     <li>",
"      Expiratory wheezes, high-pitched breath sounds, are caused by oscillation of air through a narrowed airway; they are more common in bronchiolitis and interstitial pneumonitis",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     ETIOLOGIC AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A large number of microorganisms have been implicated as etiologic agents of pneumonia in children (",
"    <a class=\"graphic graphic_table graphicRef54228 graphicRef71263 \" href=\"UTD.htm?31/18/32047\">",
"     table 1A-B",
"    </a>",
"    ). The agents commonly responsible vary according to the age of the child and the setting in which the infection is acquired.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Community-acquired pneumonia",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;The true prevalence of the various etiologic agents in community-acquired pneumonia (CAP) in children is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2938/abstract/25\">",
"     25",
"    </a>",
"    ]. Studies investigating the etiology of childhood pneumonia have been performed in populations of various ages, in various settings, and using a variety of microbiologic techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2938/abstract/26-37\">",
"     26-37",
"    </a>",
"    ]. Because direct culture of infected lung tissue requires invasive techniques, published studies primarily use laboratory tests that provide indirect evidence of etiology. These indirect methods include nasopharyngeal culture, blood culture, polymerase chain reaction, and serology. In addition to the use of indirect methods, interpretation of the results is hampered by the failure to identify an organism in 15 to 35 percent of cases and the frequency of mixed infections (in 23 to 33 percent of cases) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2938/abstract/2\">",
"     2",
"    </a>",
"    ]. Most of these studies were performed before the licensure of the pneumococcal conjugate vaccine [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2938/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite these problems, systematic reviews have identified some consistent trends and conclusions regarding the etiology of CAP in children, which are listed below [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2938/abstract/2,25\">",
"     2,25",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <em>",
"       S. pneumoniae",
"      </em>",
"      is the most common bacterial cause of pneumonia in children [",
"      <a class=\"abstract\" href=\"UTD.htm?2/55/2938/abstract/9,39\">",
"       9,39",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Viruses alone account for 14 to 35 percent of cases, and up to 50 percent of cases in young children",
"     </li>",
"     <li>",
"      Viruses are more commonly identified in children younger than five years",
"     </li>",
"     <li>",
"      In children older than five years,",
"      <em>",
"       Mycoplasma pneumoniae",
"      </em>",
"      , and",
"      <em>",
"       Chlamydophila",
"      </em>",
"      (formerly",
"      <em>",
"       Chlamydia",
"      </em>",
"      )",
"      <em>",
"       pneumoniae",
"      </em>",
"      are more common [",
"      <a class=\"abstract\" href=\"UTD.htm?2/55/2938/abstract/40,41\">",
"       40,41",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In some areas in which community-associated methicillin-resistant",
"    <em>",
"     Staphylococcus aureus",
"    </em>",
"    (CA-MRSA) is a major issue, CA-MRSA is becoming an important cause of CAP complicated by empyema and necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2938/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. When associated with influenza, MRSA CAP can be particularly severe [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2938/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/34/9770?source=see_link\">",
"     \"Epidemiology; clinical presentation; and evaluation of parapneumonic effusion and empyema in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/49/24346?source=see_link&amp;anchor=H14#H14\">",
"     \"Clinical features and diagnosis of seasonal influenza in children\", section on 'Bacterial coinfection'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/21/30042?source=see_link&amp;anchor=H12#H12\">",
"     \"Epidemiology and clinical spectrum of methicillin-resistant Staphylococcus aureus infections in children\", section on 'Epidemiology and risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     In neonates",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiology of pneumonia in neonates (infants &lt;28 days of age) is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/0/21512?source=see_link&amp;anchor=H8#H8\">",
"     \"Neonatal pneumonia\", section on 'Microbiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     In infants",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described below, viruses are the most common etiology of CAP in children younger than five years, including infants. However, infants younger than one year also may develop \"afebrile pneumonia of infancy.\" Afebrile pneumonia of infancy is a syndrome generally seen between two weeks and three to four months of life. It is classically caused by",
"    <em>",
"     Chlamydia trachomatis",
"    </em>",
"    , but other agents, such as cytomegalovirus (CMV),",
"    <em>",
"     Mycoplasma hominis",
"    </em>",
"    , and",
"    <em>",
"     Ureaplasma urealyticum",
"    </em>",
"    , also are implicated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/21/27992?source=see_link&amp;anchor=H7#H7\">",
"     \"Chlamydia trachomatis infections in the newborn\", section on 'Pneumonia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Infants with severe",
"    <em>",
"     Bordetella pertussis",
"    </em>",
"    infection also may develop pneumonia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/55/16248?source=see_link&amp;anchor=H15#H15\">",
"     \"Clinical features and diagnosis of Bordetella pertussis infection in infants and children\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     In children &lt;5 years",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Viruses &ndash; Viruses are the most common etiology of CAP in older infants and children younger than five years of age [",
"      <a class=\"abstract\" href=\"UTD.htm?2/55/2938/abstract/2,25\">",
"       2,25",
"      </a>",
"      ]. However, bacterial pathogens, including",
"      <em>",
"       S. pneumoniae",
"      </em>",
"      ,",
"      <em>",
"       S. aureus",
"      </em>",
"      , and",
"      <em>",
"       S. pyogenes",
"      </em>",
"      , also are important because they are associated with increased morbidity and mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?2/55/2938/abstract/43,44,46\">",
"       43,44,46",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Respiratory syncytial virus (RSV), a member of the",
"      <em>",
"       Paramyxoviridae",
"      </em>",
"      virus family, is the most common viral pathogen responsible for pneumonia in children younger than five years [",
"      <a class=\"abstract\" href=\"UTD.htm?2/55/2938/abstract/32\">",
"       32",
"      </a>",
"      ]. RSV pneumonia frequently represents an extension of bronchiolitis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/44/16074?source=see_link&amp;anchor=H7#H7\">",
"       \"Bronchiolitis in infants and children: Clinical features and diagnosis\", section on 'Clinical features'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/56/7050?source=see_link&amp;anchor=H15#H15\">",
"       \"Respiratory syncytial virus infection: Clinical features and diagnosis\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Other viral causes of pneumonia in children younger than five years include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Influenza A and B viruses. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/49/24346?source=see_link&amp;anchor=H9687278#H9687278\">",
"       \"Clinical features and diagnosis of seasonal influenza in children\", section on 'Pneumonia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Parainfluenza viruses, usually type 3. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36808?source=see_link&amp;anchor=H10#H10\">",
"       \"Parainfluenza viruses in children\", section on 'Clinical presentation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A number of adenovirus serotypes (1, 2, 3, 4, 5, 7, 14, 21, and 35) have been reported to cause pneumonia; serotypes 3, 7, and 21 have been associated with severe and complicated pneumonia [",
"      <a class=\"abstract\" href=\"UTD.htm?2/55/2938/abstract/47\">",
"       47",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/21/39257?source=see_link&amp;anchor=H9#H9\">",
"       \"Epidemiology and clinical manifestations of adenovirus infection\", section on 'Clinical presentation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Human metapneumovirus, identified in 2001, is a common cause of lower respiratory tract infections in children; most children have been infected by five years of age. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/33/33304?source=see_link\">",
"       \"Human metapneumovirus infections\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Rhinovirus has been implicated as a cause of pneumonia using PCR assays [",
"      <a class=\"abstract\" href=\"UTD.htm?2/55/2938/abstract/48\">",
"       48",
"      </a>",
"      ], but its etiologic role is questioned [",
"      <a class=\"abstract\" href=\"UTD.htm?2/55/2938/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Coronaviruses, including the severe acute respiratory syndrome (SARS) virus and the New Haven coronavirus, also cause respiratory tract infections in children younger than five years [",
"      <a class=\"abstract\" href=\"UTD.htm?2/55/2938/abstract/50\">",
"       50",
"      </a>",
"      ]. However, their clinical impact has yet to be fully determined [",
"      <a class=\"abstract\" href=\"UTD.htm?2/55/2938/abstract/51\">",
"       51",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/21/17753?source=see_link\">",
"       \"Severe acute respiratory syndrome (SARS)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/13/41176?source=see_link\">",
"       \"Coronaviruses\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Human bocavirus and human parechovirus types 1, 2, and 3 also have been implicated as a cause of lower respiratory tract infections in children [",
"      <a class=\"abstract\" href=\"UTD.htm?2/55/2938/abstract/52-54\">",
"       52-54",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bacteria &ndash; Important bacterial causes of pneumonia in preschool children include",
"      <em>",
"       S. pneumoniae",
"      </em>",
"      ,",
"      <em>",
"       H. influenzae type b",
"      </em>",
"      ,",
"      <em>",
"       nontypeable H. influenza",
"      </em>",
"      ,",
"      <em>",
"       Moraxella catarrhalis",
"      </em>",
"      ,",
"      <em>",
"       S. aureus",
"      </em>",
"      ,",
"      <em>",
"       S. pyogenes",
"      </em>",
"      , and atypical bacteria.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <em>",
"       S. pneumoniae",
"      </em>",
"      is the single most common bacterial pathogen causing pneumonia in all patients beyond the first few weeks of life [",
"      <a class=\"abstract\" href=\"UTD.htm?2/55/2938/abstract/9,39\">",
"       9,39",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/11/35001?source=see_link&amp;anchor=H3#H3\">",
"       \"Pneumococcal pneumonia in children\", section on 'Epidemiology'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <em>",
"       H. influenzae",
"      </em>",
"      type b is a rare cause of pneumonia in countries with universal childhood immunization.",
"     </li>",
"     <li>",
"      <em>",
"       S. aureus",
"      </em>",
"      (particularly community-associated MRSA, CA-MRSA) and",
"      <em>",
"       S. pyogenes",
"      </em>",
"      are becoming increasingly frequent causes of CAP, particularly those complicated by necrosis and empyema [",
"      <a class=\"abstract\" href=\"UTD.htm?2/55/2938/abstract/43,55\">",
"       43,55",
"      </a>",
"      ]. In addition, these organisms occasionally cause pneumonia and frequently are seen following influenza and chickenpox, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?2/55/2938/abstract/44,45\">",
"       44,45",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33480?source=see_link\">",
"       \"Clinical features of varicella-zoster virus infection: Chickenpox\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/49/24346?source=see_link&amp;anchor=H9687278#H9687278\">",
"       \"Clinical features and diagnosis of seasonal influenza in children\", section on 'Pneumonia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The prevalence of",
"      <em>",
"       M. pneumoniae",
"      </em>",
"      and",
"      <em>",
"       C. pneumoniae",
"      </em>",
"      may be increasing in preschool children with CAP [",
"      <a class=\"abstract\" href=\"UTD.htm?2/55/2938/abstract/25,56\">",
"       25,56",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33062?source=see_link\">",
"       \"Pneumonia caused by Chlamydophila (Chlamydia) species in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/35/6713?source=see_link&amp;anchor=H4#H4\">",
"       \"Mycoplasma pneumoniae infection in children\", section on 'Epidemiology'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     In children &ge;5 years",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <em>",
"       S. pneumoniae",
"      </em>",
"      is the most common typical bacterial cause of pneumonia in children older than five years (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/11/35001?source=see_link&amp;anchor=H3#H3\">",
"       \"Pneumococcal pneumonia in children\", section on 'Epidemiology'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <em>",
"       M. pneumoniae",
"      </em>",
"      is more common among children &ge;5 years than among younger children (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/35/6713?source=see_link&amp;anchor=H4#H4\">",
"       \"Mycoplasma pneumoniae infection in children\", section on 'Epidemiology'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <em>",
"       C. pneumoniae",
"      </em>",
"      also is emerging as a frequent cause of pneumonia in older children and young adults (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33062?source=see_link\">",
"       \"Pneumonia caused by Chlamydophila (Chlamydia) species in children\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Aspiration pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;When there is a predisposition to aspiration, pneumonia may be caused by anaerobic oral flora, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Anaerobic streptococci (eg,",
"      <em>",
"       Peptostreptococcus",
"      </em>",
"      )",
"     </li>",
"     <li>",
"      <em>",
"       Fusobacterium",
"      </em>",
"      spp",
"     </li>",
"     <li>",
"      <em>",
"       Bacteroides",
"      </em>",
"      spp",
"     </li>",
"     <li>",
"      <em>",
"       Prevotella melaninogenica",
"      </em>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Risk factors for aspiration include a history of seizure, anesthesia, or other episode of reduced level of consciousness, neurologic disease, dysphagia, gastroesophageal reflux, alcohol or substance abuse, use of a nasogastric tube, or foreign body aspiration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Nosocomial pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nosocomial bacterial pneumonia is usually caused by gram-negative bacilli or",
"    <em>",
"     S. aureus",
"    </em>",
"    . Nosocomial pneumonia frequently occurs in intensive care units where mechanical ventilation, indwelling catheters, and administration of broad-spectrum antibiotics are common. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/48/25354?source=see_link&amp;anchor=H22#H22\">",
"     \"Inpatient treatment of pneumonia in children\", section on 'Nosocomial pneumonia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, during the winter respiratory viral season, all patients in a medical care environment are at risk for nosocomial pneumonia caused by RSV, parainfluenza, and influenza viruses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/49/24346?source=see_link\">",
"     \"Clinical features and diagnosis of seasonal influenza in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36808?source=see_link&amp;anchor=H10#H10\">",
"     \"Parainfluenza viruses in children\", section on 'Clinical presentation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/56/7050?source=see_link&amp;anchor=H11#H11\">",
"     \"Respiratory syncytial virus infection: Clinical features and diagnosis\", section on 'Transmission'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Special populations",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Immunocompromised",
"    </span>",
"    &nbsp;&mdash;&nbsp;The causes of pneumonia in immunocompromised hosts include all of the pathogens mentioned above, as well as a variety of other organisms, as discussed below.",
"   </p>",
"   <p>",
"    Gram-negative bacilli and",
"    <em>",
"     S. aureus",
"    </em>",
"    are common etiologies in neutropenic patients or in those with white blood cell (WBC) defects. Clinically significant Legionellosis usually is seen only in immunocompromised hosts with an exposure to an aquatic reservoir of",
"    <em>",
"     Legionella pneumophila",
"    </em>",
"    , such as a river, lake, air-conditioning cooling tower, or water distribution systems [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2938/abstract/21,57\">",
"     21,57",
"    </a>",
"    ]. However, seroepidemiologic studies suggest that subclinical or minor infections occur in children [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2938/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/58/32680?source=see_link\">",
"     \"Epidemiology and pathogenesis of Legionella infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Opportunistic fungi, such as",
"    <em>",
"     Aspergillus",
"    </em>",
"    spp and",
"    <em>",
"     Fusarium",
"    </em>",
"    spp, also are a concern in neutropenic patients and in those receiving immunosuppressive therapies that impair the cell-mediated response. One of the more common pneumonia pathogens diagnosed in HIV-infected patients is",
"    <em>",
"     Pneumocystis jirovecii",
"    </em>",
"    , which was formerly called",
"    <em>",
"     Pneumocystis carinii",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2938/abstract/60\">",
"     60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34616?source=see_link\">",
"     \"Epidemiology and clinical manifestations of invasive aspergillosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/18/6439?source=see_link\">",
"     \"Mycology, pathogenesis, and epidemiology of Fusarium infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/3/3130?source=see_link&amp;anchor=H18840512#H18840512\">",
"     \"Natural history and classification of pediatric HIV infection\", section on 'Pneumocystis jirovecii pneumonia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Viral causes of pneumonia, which may be life-threatening in the immunocompromised host, include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rubeola (Hecht giant-cell pneumonia) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/11/43192?source=see_link&amp;anchor=H21#H21\">",
"       \"Clinical presentation and diagnosis of measles\", section on 'Immunocompromised patients'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Varicella-zoster virus (VZV) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33480?source=see_link&amp;anchor=H15#H15\">",
"       \"Clinical features of varicella-zoster virus infection: Chickenpox\", section on 'Pneumonia'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      CMV (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/51/36664?source=see_link&amp;anchor=H13#H13\">",
"       \"Cytomegalovirus infection and disease in newborns, infants, children and adolescents\", section on 'CMV infections in immunocompromised hosts'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Epstein-Barr virus (EBV), which may be the trigger for lymphocytic interstitial pneumonitis, an indolent but progressive process that occurs in children infected with HIV (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/55/14202?source=see_link\">",
"       \"Clinical manifestations and treatment of Epstein-Barr virus infection\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/10/7335?source=see_link&amp;anchor=H4#H4\">",
"       \"Lymphocytic interstitial pneumonitis in children\", section on 'Pathogenesis'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Cystic fibrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Young children with cystic fibrosis frequently are infected with",
"    <em>",
"     S. aureus",
"    </em>",
"    ,",
"    <em>",
"     P. aeruginosa",
"    </em>",
"    , and",
"    <em>",
"     H. influenzae",
"    </em>",
"    (mostly nontypeable strains). Later in the course of the disease, multiple drug-resistant gram-negative organisms, such as",
"    <em>",
"     Burkholderia cepacia",
"    </em>",
"    ,",
"    <em>",
"     Stenotrophomonas maltophilia",
"    </em>",
"    , and",
"    <em>",
"     Achromobacter xylosoxidans",
"    </em>",
"    , can be recovered.",
"    <em>",
"     Aspergillus",
"    </em>",
"    spp and nontuberculous mycobacteria also may cause disease in this population. Cystic fibrosis lung disease is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27351?source=see_link\">",
"     \"Cystic fibrosis: Clinical manifestations of pulmonary disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39274?source=see_link\">",
"     \"Cystic fibrosis: Overview of the treatment of lung disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/22/41322?source=see_link\">",
"     \"Cystic fibrosis: Antibiotic therapy for lung disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Sickle cell anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of pneumonia is increased in children with sickle cell anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2938/abstract/61\">",
"     61",
"    </a>",
"    ]. Atypical bacterial pathogens appear to be most frequent and are more commonly associated with the acute chest syndrome. Other bacterial causes of pneumonia in children with sickle cell anemia include",
"    <em>",
"     S. pneumoniae",
"    </em>",
"    ,",
"    <em>",
"     S. aureus",
"    </em>",
"    , and",
"    <em>",
"     H. influenzae",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/55/2938/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/26/16810?source=see_link&amp;anchor=H5#H5\">",
"     \"The acute chest syndrome in children and adolescents with sickle cell disease\", section on 'Infection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Environmental considerations",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Geography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Residence in or travel to specific geographic areas should suggest endemic pathogens:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tuberculosis is most common in immigrants from countries with a high prevalence of infection (eg, countries throughout Asia, Africa, Latin America, and Eastern Europe) (",
"      <a class=\"graphic graphic_figure graphicRef55097 \" href=\"UTD.htm?27/12/27846\">",
"       figure 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/13/18649?source=see_link\">",
"       \"Epidemiology of tuberculosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Measles pneumonia is common in the developing world. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/11/43192?source=see_link\">",
"       \"Clinical presentation and diagnosis of measles\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <em>",
"       Coccidioides immitis",
"      </em>",
"      is endemic to the southwestern United States, northern Mexico, and parts of Central and South America. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/26/425?source=see_link\">",
"       \"Primary coccidioidal infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <em>",
"       Blastomyces dermatitidis",
"      </em>",
"      , causing blastomycosis, is endemic in the southeastern and central states and the midwestern states bordering the Great Lakes. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/4/79?source=see_link\">",
"       \"Mycology, pathogenesis, and epidemiology of blastomycosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29912?source=see_link\">",
"       \"Treatment of blastomycosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <em>",
"       Histoplasma capsulatum",
"      </em>",
"      is in the Ohio, Missouri, and Mississippi river valleys in the United States. It also occurs in Canada, Central America, eastern and southern Europe, parts of Africa, eastern Asia, and Australia. Activities potentially leading to exposure to bird droppings and bat guano may be suggestive. These include gardening, construction, cleaning of barns and outbuildings, and spelunking. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/24/42376?source=see_link\">",
"       \"Pathogenesis and clinical features of pulmonary histoplasmosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/23/21881?source=see_link\">",
"       \"Diagnosis and treatment of pulmonary histoplasmosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In the United States, hantavirus cardiopulmonary syndrome (acute febrile illness associated with respiratory failure, shock, and high mortality) occurs predominantly west of the Mississippi River (in the &ldquo;four corners&rdquo; region where the borders of Colorado, New Mexico, Arizona, and Utah meet) after environmental exposure to infected deer mouse (",
"      <em>",
"       Peromyscus maniculatus",
"      </em>",
"      ) saliva, urine, or feces. Activities associated with exposure include cleaning of barns and outbuildings, trapping rodents, animal herding, and farming with hand tools. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13848?source=see_link\">",
"       \"Epidemiology and diagnosis of hantavirus infections\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/14/38119?source=see_link\">",
"       \"Hantavirus cardiopulmonary syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Animal exposures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histoplasmosis is associated with exposure to bird droppings and bat guano, and hantavirus infection is associated with exposure to an infected deer mouse. Other causes of pneumonia that are associated with animal exposure include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <em>",
"       Chlamydophila",
"      </em>",
"      (formerly",
"      <em>",
"       Chlamydia",
"      </em>",
"      )",
"      <em>",
"       psittaci",
"      </em>",
"      (psittacosis), which is transmitted to man predominantly from birds (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/14/8425?source=see_link\">",
"       \"Psittacosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <em>",
"       Coxiella burnetii",
"      </em>",
"      (Q fever), which is associated with exposure to parturient sheep, goats, cattle, and cats (or exposure to",
"      <span class=\"nowrap\">",
"       dust/soil",
"      </span>",
"      contaminated by these animals) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/53/22357?source=see_link\">",
"       \"Microbiology and epidemiology of Q fever\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/13/12502?source=see_link\">",
"       \"Clinical manifestations and diagnosis of Q fever\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Other exposures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exposure to individuals at high risk for tuberculosis is a risk factor for the development of tuberculosis in children. High-risk individuals include the homeless, recent immigrants from endemic regions (",
"    <a class=\"graphic graphic_figure graphicRef55097 \" href=\"UTD.htm?27/12/27846\">",
"     figure 2",
"    </a>",
"    ), incarcerated individuals, and HIV-infected patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/13/18649?source=see_link\">",
"     \"Epidemiology of tuberculosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?14/17/14611?source=see_link\">",
"       \"Patient information: Pneumonia in children (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pneumonia is more common in children younger than five years of age than in older children and adolescents. Risk factors for pneumonia include environmental crowding, having school-aged siblings, and underlying cardiopulmonary and other medical disorders. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Epidemiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Pneumonia can be caused by a large number of microorganisms (",
"    <a class=\"graphic graphic_table graphicRef54228 graphicRef71263 \" href=\"UTD.htm?31/18/32047\">",
"     table 1A-B",
"    </a>",
"    ). The agents commonly responsible vary according to the age of the child and the setting in which the infection is acquired. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Etiologic agents'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In children younger than five years, viruses are most common. However, bacterial pathogens, including",
"      <em>",
"       S. pneumoniae",
"      </em>",
"      ,",
"      <em>",
"       S. aureus",
"      </em>",
"      , and",
"      <em>",
"       S. pyogenes",
"      </em>",
"      , also are important. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'In children &lt;5 years'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In otherwise-healthy children older than five years,",
"      <em>",
"       S. pneumonia",
"      </em>",
"      ,",
"      <em>",
"       M. pneumoniae",
"      </em>",
"      , and",
"      <em>",
"       Chlamydophila pneumoniae",
"      </em>",
"      are most common. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'In children &ge;5 years'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Community-associated methicillin-resistant",
"      <em>",
"       S. aureus",
"      </em>",
"      (CA-MRSA) is an increasingly important pathogen in children of all ages, particularly in those with necrotizing pneumonia.",
"      <em>",
"       S. pneumoniae",
"      </em>",
"      is another frequent cause of necrotizing pneumonia. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Aspiration pneumonia is usually caused by anaerobic oral flora. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Aspiration pneumonia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nosocomial pneumonia is usually caused by gram-negative bacilli or",
"      <em>",
"       Staphylococcus aureus",
"      </em>",
"      . (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Nosocomial pneumonia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2938/abstract/1\">",
"      Rudan I, Boschi-Pinto C, Biloglav Z, et al. Epidemiology and etiology of childhood pneumonia. Bull World Health Organ 2008; 86:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2938/abstract/2\">",
"      Harris M, Clark J, Coote N, et al. British Thoracic Society guidelines for the management of community acquired pneumonia in children: update 2011. Thorax 2011; 66 Suppl 2:ii1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2938/abstract/3\">",
"      Margolis P, Gadomski A. The rational clinical examination. Does this infant have pneumonia? JAMA 1998; 279:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2938/abstract/4\">",
"      Fiore AE, Shay DK, Broder K, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep 2009; 58:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2938/abstract/5\">",
"      Jokinen C, Heiskanen L, Juvonen H, et al. Incidence of community-acquired pneumonia in the population of four municipalities in eastern Finland. Am J Epidemiol 1993; 137:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2938/abstract/6\">",
"      Wardlaw T, Salama P, Johansson EW, Mason E. Pneumonia: the leading killer of children. Lancet 2006; 368:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2938/abstract/7\">",
"      Glezen P, Denny FW. Epidemiology of acute lower respiratory disease in children. N Engl J Med 1973; 288:498.",
"     </a>",
"    </li>",
"    <li>",
"     Boyer KM. Nonbacterial pneumonia. In: Textbook of Pediatric Infectious Diseases, 6th, Feigin RD, Cherry JD, Demmler-Harrison GJ, Kaplan SL (Eds), Saunders, Philadelphia 2009. p.289.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2938/abstract/9\">",
"      Pelton SI, Hammerschlag MR. Overcoming current obstacles in the management of bacterial community-acquired pneumonia in ambulatory children. Clin Pediatr (Phila) 2005; 44:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2938/abstract/10\">",
"      Green GM, Carolin D. The depressant effect of cigarette smoke on the in vitro antibacterial activity of alveolar macrophages. N Engl J Med 1967; 276:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2938/abstract/11\">",
"      MacGregor RR. Alcohol and immune defense. JAMA 1986; 256:1474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2938/abstract/12\">",
"      Kaplan SL, Mason EO Jr, Wald ER, et al. Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. Pediatrics 2004; 113:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2938/abstract/13\">",
"      Grijalva CG, Nuorti JP, Arbogast PG, et al. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 2007; 369:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2938/abstract/14\">",
"      Zhou F, Kyaw MH, Shefer A, et al. Health care utilization for pneumonia in young children after routine pneumococcal conjugate vaccine use in the United States. Arch Pediatr Adolesc Med 2007; 161:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2938/abstract/15\">",
"      Kronman MP, Hersh AL, Feng R, et al. Ambulatory visit rates and antibiotic prescribing for children with pneumonia, 1994-2007. Pediatrics 2011; 127:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2938/abstract/16\">",
"      Resti M, Moriondo M, Cortimiglia M, et al. Community���acquired bacteremic pneumococcal pneumonia in children: diagnosis and serotyping by real���time polymerase chain reaction using blood samples. Clin Infect Dis 2010; 51:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2938/abstract/17\">",
"      Blaschke AJ, Heyrend C, Byington CL, et al. Molecular analysis improves pathogen identification and epidemiologic study of pediatric parapneumonic empyema. Pediatr Infect Dis J 2011; 30:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2938/abstract/18\">",
"      Madhi SA, Klugman KP, Vaccine Trialist Group. A role for Streptococcus pneumoniae in virus-associated pneumonia. Nat Med 2004; 10:811.",
"     </a>",
"    </li>",
"    <li>",
"     Mani CS, Murray DL. Acute pneumonia and its complications. In: Principles and Practice of Pediatric Infectious Diseases, 4th, Long SS, Pickering LK, Prober CG.  (Eds), Elsevier Saunders, Edinburgh 2012. p.235.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2938/abstract/20\">",
"      Aherne W, Bird T, Court SD, et al. Pathological changes in virus infections of the lower respiratory tract in children. J Clin Pathol 1970; 23:7.",
"     </a>",
"    </li>",
"    <li>",
"     Klein JO. Bacterial pneumonias. In: Textbook of Pediatric Infectious Diseases, 6th, Feigin RD, Cherry JD, Demmler-Harrison GJ, Kaplan SL (Eds), Saunders, Philadelphia 2009. p.302.",
"    </li>",
"    <li>",
"     Baltimore RS. Pneumonia. In: Pediatric Infectious Diseases: Principles and Practice, 2nd ed, Jenson HB, Baltimore RS (Eds), WB Saunders, Philadelphia 2002. p.794.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2938/abstract/23\">",
"      Dakhama A, Lee YM, Gelfand EW. Virus-induced airway dysfunction: pathogenesis and biomechanisms. Pediatr Infect Dis J 2005; 24:S159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2938/abstract/24\">",
"      Mikami R, Murao M, Cugell DW, et al. International Symposium on Lung Sounds. Synopsis of proceedings. Chest 1987; 92:342.",
"     </a>",
"    </li>",
"    <li>",
"     Health Policy and Clinical Effectiveness Department. Cincinnati Children's Hospital Medical Center. Community acquired pneumonia. www.cincinnatichildrens.org/svc/alpha/h/health-policy/ev-based/pneumonia.htm (Accessed on August 11, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2938/abstract/26\">",
"      Isaacs D. Problems in determining the etiology of community-acquired childhood pneumonia. Pediatr Infect Dis J 1989; 8:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2938/abstract/27\">",
"      Wubbel L, Muniz L, Ahmed A, et al. Etiology and treatment of community-acquired pneumonia in ambulatory children. Pediatr Infect Dis J 1999; 18:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2938/abstract/28\">",
"      Korppi M, Heiskanen-Kosma T, Jalonen E, et al. Aetiology of community-acquired pneumonia in children treated in hospital. Eur J Pediatr 1993; 152:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2938/abstract/29\">",
"      Claesson BA, Trollfors B, Brolin I, et al. Etiology of community-acquired pneumonia in children based on antibody responses to bacterial and viral antigens. Pediatr Infect Dis J 1989; 8:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2938/abstract/30\">",
"      Ruuskanen O, Nohynek H, Ziegler T, et al. Pneumonia in childhood: etiology and response to antimicrobial therapy. Eur J Clin Microbiol Infect Dis 1992; 11:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2938/abstract/31\">",
"      Gendrel D, Raymond J, Moulin F, et al. Etiology and response to antibiotic therapy of community-acquired pneumonia in French children. Eur J Clin Microbiol Infect Dis 1997; 16:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2938/abstract/32\">",
"      Heiskanen-Kosma T, Korppi M, Jokinen C, et al. Etiology of childhood pneumonia: serologic results of a prospective, population-based study. Pediatr Infect Dis J 1998; 17:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2938/abstract/33\">",
"      Numazaki K, Chiba S, Umetsu M, et al. Etiological agents of lower respiratory tract infections in Japanese children. In Vivo 2004; 18:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2938/abstract/34\">",
"      Turner RB, Lande AE, Chase P, et al. Pneumonia in pediatric outpatients: cause and clinical manifestations. J Pediatr 1987; 111:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2938/abstract/35\">",
"      Vuori E, Peltola H, Kallio MJ, et al. Etiology of pneumonia and other common childhood infections requiring hospitalization and parenteral antimicrobial therapy. SE-TU Study Group. Clin Infect Dis 1998; 27:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2938/abstract/36\">",
"      Michelow IC, Olsen K, Lozano J, et al. Epidemiology and clinical characteristics of community-acquired pneumonia in hospitalized children. Pediatrics 2004; 113:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2938/abstract/37\">",
"      Cevey-Macherel M, Galetto-Lacour A, Gervaix A, et al. Etiology of community-acquired pneumonia in hospitalized children based on WHO clinical guidelines. Eur J Pediatr 2009; 168:1429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2938/abstract/38\">",
"      Bradley JS. Management of community-acquired pediatric pneumonia in an era of increasing antibiotic resistance and conjugate vaccines. Pediatr Infect Dis J 2002; 21:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2938/abstract/39\">",
"      Heiskanen-Kosma T, Korppi M, Leinonen M. Serologically indicated pneumococcal pneumonia in children: a population-based study in primary care settings. APMIS 2003; 111:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2938/abstract/40\">",
"      Korppi M, Heiskanen-Kosma T, Kleemola M. Incidence of community-acquired pneumonia in children caused by Mycoplasma pneumoniae: serological results of a prospective, population-based study in primary health care. Respirology 2004; 9:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2938/abstract/41\">",
"      Kurz H, G&ouml;pfrich H, Wabnegger L, Apfalter P. Role of Chlamydophila pneumoniae in children hospitalized for community-acquired pneumonia in Vienna, Austria. Pediatr Pulmonol 2009; 44:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2938/abstract/42\">",
"      Carrillo-Marquez MA, Hulten KG, Hammerman W, et al. Staphylococcus aureus pneumonia in children in the era of community-acquired methicillin-resistance at Texas Children's Hospital. Pediatr Infect Dis J 2011; 30:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2938/abstract/43\">",
"      Schwartz KL, Nourse C. Panton-Valentine leukocidin-associated Staphylococcus aureus necrotizing pneumonia in infants: a report of four cases and review of the literature. Eur J Pediatr 2012; 171:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2938/abstract/44\">",
"      Hageman JC, Uyeki TM, Francis JS, et al. Severe community-acquired pneumonia due to Staphylococcus aureus, 2003-04 influenza season. Emerg Infect Dis 2006; 12:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2938/abstract/45\">",
"      Centers for Disease Control and Prevention (CDC). Severe methicillin-resistant Staphylococcus aureus community-acquired pneumonia associated with influenza--Louisiana and Georgia, December 2006-January 2007. MMWR Morb Mortal Wkly Rep 2007; 56:325.",
"     </a>",
"    </li>",
"    <li>",
"     Miller MA, Ben-Ami T, Daum RS. Bacterial pneumonia in neonates and older children. In: Pediatric Respiratory Medicine, Taussig LM, Landau LI (Eds), Mosby, St. Louis 1999. p.595.",
"    </li>",
"    <li>",
"     Cherry JD, Chen TK. Adenoviruses. In: Textbook of Pediatric Infectious Diseases, 6th, Feigin RD, Cherry JD, Demmler-Harrison GJ, Kaplan SL (Eds), Saunders, Philadelphia 2009. p.1949.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2938/abstract/48\">",
"      Juv&eacute;n T, Mertsola J, Waris M, et al. Etiology of community-acquired pneumonia in 254 hospitalized children. Pediatr Infect Dis J 2000; 19:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2938/abstract/49\">",
"      McIntosh K. Community-acquired pneumonia in children. N Engl J Med 2002; 346:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2938/abstract/50\">",
"      Heugel J, Martin ET, Kuypers J, Englund JA. Coronavirus-associated pneumonia in previously healthy children. Pediatr Infect Dis J 2007; 26:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2938/abstract/51\">",
"      Kahn JS, McIntosh K. History and recent advances in coronavirus discovery. Pediatr Infect Dis J 2005; 24:S223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2938/abstract/52\">",
"      Longtin J, Bastien M, Gilca R, et al. Human bocavirus infections in hospitalized children and adults. Emerg Infect Dis 2008; 14:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2938/abstract/53\">",
"      Abed Y, Boivin G. Human parechovirus types 1, 2 and 3 infections in Canada. Emerg Infect Dis 2006; 12:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2938/abstract/54\">",
"      Don M, S&ouml;derlund-Venermo M, Valent F, et al. Serologically verified human bocavirus pneumonia in children. Pediatr Pulmonol 2010; 45:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2938/abstract/55\">",
"      Al-Kaabi N, Solh Z, Pacheco S, et al. A Comparison of group A Streptococcus versus Streptococcus pneumoniae pneumonia. Pediatr Infect Dis J 2006; 25:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2938/abstract/56\">",
"      Esposito S, Bosis S, Cavagna R, et al. Characteristics of Streptococcus pneumoniae and atypical bacterial infections in children 2-5 years of age with community-acquired pneumonia. Clin Infect Dis 2002; 35:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2938/abstract/57\">",
"      Greenberg D, Chiou CC, Famigilleti R, et al. Problem pathogens: paediatric legionellosis--implications for improved diagnosis. Lancet Infect Dis 2006; 6:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2938/abstract/58\">",
"      Muldoon RL, Jaecker DL, Kiefer HK. Legionnaires' disease in children. Pediatrics 1981; 67:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2938/abstract/59\">",
"      Andersen RD, Lauer BA, Fraser DW, et al. Infections with Legionella pneumophila in children. J Infect Dis 1981; 143:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2938/abstract/60\">",
"      Stringer JR, Beard CB, Miller RF, Wakefield AE. A new name (Pneumocystis jiroveci) for Pneumocystis from humans. Emerg Infect Dis 2002; 8:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/55/2938/abstract/61\">",
"      De Ceulaer K, McMullen KW, Maude GH, et al. Pneumonia in young children with homozygous sickle cell disease: risk and clinical features. Eur J Pediatr 1985; 144:255.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5979 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-89.32.226.102-21F53BA666-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_55_2938=[""].join("\n");
var outline_f2_55_2938=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H31\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Incidence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Seasonality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Effect of vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Acquisition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Normal host defense",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Patterns of pneumonia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Examination findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      ETIOLOGIC AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Community-acquired pneumonia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Overview",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - In neonates",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - In infants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - In children &lt;5 years",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - In children &ge;5 years",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Aspiration pneumonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Nosocomial pneumonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Special populations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Immunocompromised",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Cystic fibrosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Sickle cell anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Environmental considerations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Geography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Animal exposures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Other exposures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5979\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5979|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?19/30/19941\" title=\"diagnostic image 1\">",
"      Necrotizing pneumonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?31/14/31973\" title=\"diagnostic image 2\">",
"      LIP CXR and HRCT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5979|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/33/27166\" title=\"figure 1\">",
"      Pneumonia hospitalization children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/12/27846\" title=\"figure 2\">",
"      World map of TB incidence (2009)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5979|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/40/35468\" title=\"table 1A\">",
"      Common causes pneumonia child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/6/3183\" title=\"table 1B\">",
"      Uncommon causes pneumonia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/44/16074?source=related_link\">",
"      Bronchiolitis in infants and children: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/21/27992?source=related_link\">",
"      Chlamydia trachomatis infections in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/55/16248?source=related_link\">",
"      Clinical features and diagnosis of Bordetella pertussis infection in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38970?source=related_link\">",
"      Clinical features and diagnosis of community-acquired pneumonia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/49/24346?source=related_link\">",
"      Clinical features and diagnosis of seasonal influenza in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33480?source=related_link\">",
"      Clinical features of varicella-zoster virus infection: Chickenpox",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/13/12502?source=related_link\">",
"      Clinical manifestations and diagnosis of Q fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/55/14202?source=related_link\">",
"      Clinical manifestations and treatment of Epstein-Barr virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/11/43192?source=related_link\">",
"      Clinical presentation and diagnosis of measles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/13/41176?source=related_link\">",
"      Coronaviruses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/22/41322?source=related_link\">",
"      Cystic fibrosis: Antibiotic therapy for lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27351?source=related_link\">",
"      Cystic fibrosis: Clinical manifestations of pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39274?source=related_link\">",
"      Cystic fibrosis: Overview of the treatment of lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/51/36664?source=related_link\">",
"      Cytomegalovirus infection and disease in newborns, infants, children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/23/21881?source=related_link\">",
"      Diagnosis and treatment of pulmonary histoplasmosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/21/39257?source=related_link\">",
"      Epidemiology and clinical manifestations of adenovirus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34616?source=related_link\">",
"      Epidemiology and clinical manifestations of invasive aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/21/30042?source=related_link\">",
"      Epidemiology and clinical spectrum of methicillin-resistant Staphylococcus aureus infections in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13848?source=related_link\">",
"      Epidemiology and diagnosis of hantavirus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/58/32680?source=related_link\">",
"      Epidemiology and pathogenesis of Legionella infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/13/18649?source=related_link\">",
"      Epidemiology of tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/34/9770?source=related_link\">",
"      Epidemiology; clinical presentation; and evaluation of parapneumonic effusion and empyema in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/14/38119?source=related_link\">",
"      Hantavirus cardiopulmonary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/33/33304?source=related_link\">",
"      Human metapneumovirus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/48/25354?source=related_link\">",
"      Inpatient treatment of pneumonia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/10/7335?source=related_link\">",
"      Lymphocytic interstitial pneumonitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/53/22357?source=related_link\">",
"      Microbiology and epidemiology of Q fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/18/6439?source=related_link\">",
"      Mycology, pathogenesis, and epidemiology of Fusarium infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/4/79?source=related_link\">",
"      Mycology, pathogenesis, and epidemiology of blastomycosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/35/6713?source=related_link\">",
"      Mycoplasma pneumoniae infection in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/3/3130?source=related_link\">",
"      Natural history and classification of pediatric HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/0/21512?source=related_link\">",
"      Neonatal pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/46/27369?source=related_link\">",
"      Outpatient treatment of community-acquired pneumonia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36808?source=related_link\">",
"      Parainfluenza viruses in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/24/42376?source=related_link\">",
"      Pathogenesis and clinical features of pulmonary histoplasmosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/17/14611?source=related_link\">",
"      Patient information: Pneumonia in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7402?source=related_link\">",
"      Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/11/35001?source=related_link\">",
"      Pneumococcal pneumonia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33062?source=related_link\">",
"      Pneumonia caused by Chlamydophila (Chlamydia) species in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42489?source=related_link\">",
"      Prevention of Haemophilus influenzae infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/26/425?source=related_link\">",
"      Primary coccidioidal infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/14/8425?source=related_link\">",
"      Psittacosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/56/7050?source=related_link\">",
"      Respiratory syncytial virus infection: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/4/5194?source=related_link\">",
"      Secondhand smoke exposure: Effects in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/21/17753?source=related_link\">",
"      Severe acute respiratory syndrome (SARS)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/26/16810?source=related_link\">",
"      The acute chest syndrome in children and adolescents with sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29912?source=related_link\">",
"      Treatment of blastomycosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_55_2939="T cell subsets";
var content_f2_55_2939=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F53741&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F53741&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    The T cell subsets",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Subset",
"       </td>",
"       <td class=\"subtitle1\">",
"        Example cytokines",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CD4+ Th1",
"       </td>",
"       <td>",
"        IL-2, IFy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CD4+ Th2",
"       </td>",
"       <td>",
"        IL-4, IL-5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CD4+ Th17",
"       </td>",
"       <td>",
"        IL-17, TNF&alpha;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CD4+CD25+Foxp3 Tregs",
"       </td>",
"       <td>",
"        IL-10, IL-35",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CD8+",
"       </td>",
"       <td>",
"        IFy, TNF&alpha;, chemokines",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_55_2939=[""].join("\n");
var outline_f2_55_2939=null;
var title_f2_55_2940="Algorithm for predicting peri-procedural bleeding during PCI";
var content_f2_55_2940=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F50176&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F50176&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Algorithm for prediction of peri-procedural bleeding risk in patients undergoing percutaneous coronary intervention",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Risk factors*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Integer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intra-aortic balloon pump",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Age",
"       </td>",
"       <td>",
"        0 for &le;55 yrs; 3 for every 10 yrs over 55",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Female gender",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Glycoprotein IIb/IIIa inhibitor",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Baseline HCT &lt;39 percent for men, &lt;36 percent for women",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        LMWH within 48 hr pre-PCI",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Risk score",
"       </td>",
"       <td class=\"subtitle1\">",
"        Major bleeding (percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2-6",
"       </td>",
"       <td>",
"        1.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7-9",
"       </td>",
"       <td>",
"        2.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &ge;10",
"       </td>",
"       <td>",
"        5.4",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     eGFR: estimated glomerular filtration rate; HCT: hematocrit; LMWH: low molecular weight heparin.",
"     <br>",
"      * The presence of these risk factors leads to assignment of the corresponding integer, which are summated into a score for estimation of risk of peri-procedural bleeding after percutaneous coronary intervention.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Nikolsky E, Mehran R, Dangas G, et al. Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach. Eur Heart J 2007; 2008:1936.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_55_2940=[""].join("\n");
var outline_f2_55_2940=null;
var title_f2_55_2941="Atypical antidepressants - Pharmacokinetics";
var content_f2_55_2941=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F88061&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F88061&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Atypical antidepressants - Pharmacokinetics",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"8\" width=\"12%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Bioavailability",
"        <br/>",
"        (percent)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Time to peak plasma concentration",
"        <br/>",
"        (hours)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Primary metabolism*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Active metabolite(s)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Elimination half-life",
"        <br/>",
"        (hours)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Effect on drug metabolism",
"        <br/>",
"        (significant)*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clearance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Agomelatine",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        <p>",
"         &lt;5",
"        </p>",
"        Wide inter-individual variation; unaffected by food",
"       </td>",
"       <td>",
"        1 to 2",
"       </td>",
"       <td>",
"        <p>",
"         CYP1A2",
"        </p>",
"        Avoid use with moderate or strong inhibitors of CYP1A2",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        1 to 2",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        Hepatic; avoid use in setting of hepatic impairment or active liver disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bupropion",
"       </td>",
"       <td>",
"        Not available; modestly increased by food",
"       </td>",
"       <td>",
"        <p>",
"         Immediate release: 2",
"        </p>",
"        <p>",
"         Sustained release: 3",
"        </p>",
"        Extended release: 5",
"       </td>",
"       <td>",
"        <p>",
"         CYP2B6",
"        </p>",
"        UGT glucuronidation",
"       </td>",
"       <td>",
"        Yes (hydroxybupropion and others)",
"       </td>",
"       <td>",
"        <p>",
"         14 (parent, immediate release)",
"        </p>",
"        <p>",
"         20 (parent, extended release)",
"        </p>",
"        21-51 (active metabolites)",
"       </td>",
"       <td>",
"        Inhibits CYP2D6",
"       </td>",
"       <td>",
"        Hepatic and renal; dose adjustment may be needed in setting of renal or hepatic insufficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mirtazapine",
"       </td>",
"       <td>",
"        <p>",
"         50",
"        </p>",
"        Unaffected by food",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        <p>",
"         CYP1A2",
"        </p>",
"        <p>",
"         CYP2D6",
"        </p>",
"        CYP3A4",
"       </td>",
"       <td>",
"        Yes (",
"        <em>",
"         N",
"        </em>",
"        -desmethyl mirtazapine)",
"       </td>",
"       <td>",
"        <p>",
"         20 to 40 (parent)",
"        </p>",
"        <p>",
"         25 (active metabolite)",
"        </p>",
"        T &frac12; and serum concentrations are increased in female and older subjects",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        Hepatic and renal; dose adjustment may be needed in setting of renal or hepatic insufficiency",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CYP: cytochrome P450; UGT: uridine diphosphate glucuronosyltransferase.",
"     <br/>",
"     * Drug interactions and management suggestions may be determined by use of Lexi-Interact, the drug interactions program included with UpToDate.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Not available in the United States.",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br/>",
"     <ol>",
"      <li>",
"       Spina E, Trifir&ograve; G, Caraci F. Clinically significant drug interactions with newer antidepressants. CNS Drugs 2012; 26:39.",
"      </li>",
"      <li>",
"       Jefferson JW, Pradko JF, Muir KT. Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations. Clin Ther 2005; 27:1685.",
"      </li>",
"      <li>",
"       McAllister-Williams RH, Baldwin DS, Haddad PM, Bazire S. The use of antidepressants in clinical practice: focus on agomelatine. Hum Psychopharmacol 2010; 25:95.",
"      </li>",
"      <li>",
"       Croom KF, Perry CM, Plosker GL. Mirtazapine: a review of its use in major depression and other psychiatric disorders. CNS Drugs 2009; 23:427.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_55_2941=[""].join("\n");
var outline_f2_55_2941=null;
var title_f2_55_2942="Migraine prevalence in adolescents";
var content_f2_55_2942=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F58152&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F58152&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 554px\">",
"   <div class=\"ttl\">",
"    Migraine prevalence in adolescents",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 534px; height: 319px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_55_2942=[""].join("\n");
var outline_f2_55_2942=null;
var title_f2_55_2943="Acute pelvic pain in the premenarchal adolescent female";
var content_f2_55_2943=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F63401&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F63401&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acute pelvic pain in the premenarchal adolescent female",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 362px; height: 701px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     US: ultrasound; CT: computed tomography; RLQ: right lower quadrant; UTI: urinary tract infection; CVA: costovertebral angle.",
"     <br>",
"      * See topic on \"Causes of abdominal pain in children and adolescents\".",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_55_2943=[""].join("\n");
var outline_f2_55_2943=null;
